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ABSTRACT 
	  
The research presented in this dissertation is aimed at understanding the epigenetic 
regulation of the HIF pathway and the efficacy of treatment for retinal diseases and 
hemangioblastomas using HIF pathway inhibitors. Jumonji domain containing proteins 
demethylate tri- and dimethylated histone lysines and regulate chromatin structure. 
Substrate specificity of Jumonji domain-2 family histone demethylases (JMJD2A-C) 
was evaluated. A candidate substrate-based approach demonstrated that JMJD2A-C 
demethylate trimethylated lysine containing peptides from WIZ, CDYL1, CSB and G9a 
proteins, all constituents of transcription repression complexes. Also preference of Arg 
at –1 position and a smaller amino acid at –2 position was identified. The results 
obtained are consistent with lax substrate specificities observed for the iron (II), 2-
oxoglutarate-dependent dioxygenases, and shed new light on the role of JMJD2 family 
of KDMs during epigenetic transcriptional regulation. 
Hypoxia inducible factor (HIF) plays a critical role in cellular adaptation to 
hypoxia. Little is known about the epigenetic regulations during HIF-mediated 
transcription of pro-angiogenic genes in oxygen-dependent retinal diseases and 
hemangioblastomas. Hypoxic induction of a number of histone lysine demethylases 
(KDMs) and stem cell markers in retinal pigment epithelial cells and VHL‒/‒ renal cell 
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carcinoma cells was evaluated. Also, expression of pro-angiogenic genes (ADM, 
GDF15, HMOX1, SERPE1 and SERPB8) was determined to be dependent on KDMs 
under hypoxia. Further, treating cells with a general KDM inhibitor blocked the 
induction of these pro-angiogenic genes. Expression of stem cell markers in 
hemangioblastomas was determined to be due to activation of the HIF pathway. Further, 
honokiol, digoxin, and doxorubicin, three recently identified HIF inhibitors from natural 
sources effectively blocked the expression of stem cell markers. These results present 
the possible cytological origin of neoplastic stromal cells in hemangioblastomas. Based 
on our results we believe that inhibition of the HIF pathway is an attractive strategy for 
the treatment of hemangioblastomas and retinal diseases. Also, blocking of KDMs 
using specific inhibitors can inhibit the amplification of the HIF pathway. 
TET2 is a Fe(II), 2OG dependent dioxygenase which can demethylate 5mC in a 
CpG context, a key epigenetic modification. In this study we developed a HPLC based 
analytical method for evaluating the catalysis by recombinant TET2 protein. 
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CHAPTER I 
INTRODUCTION 
General introduction to epigenetics 
DNA of a eukaryotic cell, which is several meters long, is present in the 
nucleus and is extremely compacted. To achieve this high degree of compaction, 
DNA associates with a set of highly basic proteins called histones. This compacted 
structure is called chromatin and is made up of nucleosomes. The nucleosome 
consists of a histone octamer of the four core histones, H2A, H2B, H3, and H4 and 
147 base pairs of DNA wrapped around it. Furthermore these nucleosomes fold into 
progressively higher-order structures like a chromatin fiber and finally a 
chromosome [1]. Chromatin folding is observed to be a dynamic process, and the 
extent of folding determines the level of accessibility of DNA for processes like 
transcription, replication, and recombination. Occurrence of varying degree of 
folded chromatin regions plays an important role in regulating gene expression. The 
histone subunits have tail regions that protrude out of the nucleosome and are sites 
for extensive posttranslational modifications. These modifications modulate 
chromatin structure, thereby regulating accessibility of genes for effective 
transcription. Some of the observed post-translational modifications on histone tails 
are phosphorylation, acetylation, methylation, and sumolyation [2]. Interplay 
between these modifications determines the accessibility of DNA (Figure 1).  
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Figure 1: Chromatin architecture and epigenetic modifications observed on a 
nucleosome 
The molecular mechanisms associated with packaging of DNA and how the 
RNA polymerase II (RNAPII) machinery and its regulatory factors access this packaged 
DNA sequences remain unclear. Regulation of transcription is found to be effected by 
factors like DNA methylation, histone modifications, and small nuclear RNAs [3]. This 
mode of regulation is termed “epigenetic regulation”, denoting an inherited state of 
gene regulation independent of any encoded genetic information from within DNA. 
DNA methylation and demethylation 
Methylation of DNA and post-translational modifications of histone proteins 
play an important role in regulating the chromatin architecture and gene expression. 
One of the most widely studied epigenetic marks in normal and cancer cells DNA is 
cytosine methylation at the C5 position within the dinucleotide CpG. It has been 
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shown that 3–6% of all cytosines are methylated in normal human DNA [4]. Owing 
to the low level of occurrence of modified cytosine in the genome, it is believed that 
‘methylable’ CpG dinucleotides are distributed in the human genome in a non-
random fashion. CpG-rich regions known as the CpG islands are found in the 5′ end 
region of many genes (promoter, untranslated region and exon 1) and for expressed 
genes are usually in an unmethylated state in normal cells. This unmethylated status 
is associated with the transcriptional ability of CpG-island containing genes. 
However in cancer cells, CpG-island-promoter hypermethylation is observed, which 
leads to transcriptional silencing of tumour-suppressor genes-key for the 
tumorigenic process [5]. 
In mammals, a family of DNA methyltransferases (DNMTs) which are the 
only known enzymes to facilitate the transfer of a methyl group to cytosine from S - 
adenosylmethionine (SAM) [6] carries out DNA methylation. In mammals there are 
three enzymatically active DNMTs: DNMT1, DNMT3A and DNMT3B; and one 
related regulatory protein, DNMT3L (devoid of catalytic activity). DNMTs use a 
conserved mechanism [7] that has been studied best using the bacterial 5mC 
methyltransferase (MTase) M.HhaI [8]; [9]; [10]; [11]; [12]. Briefly, the catalysis 
involves binding of MTase to the DNA, eversion of target nucleotide to project it 
out of the double helix (‘‘base flipping’’), a conserved Cys nucleophile covalently 
attacks the cytosine C6, followed by the transfer of the methyl group from AdoMet 
to the activated cytosine C5, and the various release steps. The epigenetic effects 
associated with methylation of cytosine results in maintaining the patterns of gene 
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expression in different cell types [13]. CpG methylation is found to play an 
important role in epigenetic processes like X-chromosome inactivation [14], 
genomic imprinting (Hore et al., 2007), reprogramming in transferred nuclei [15], 
gene silencing [16]; [17], and some elements of carcinogenesis [18].  
Cytosine methylation on the DNA also occurs in the context of other known 
epigenetic modifications like histone acetylation, methylation and methyl-CpG-
binding proteins. Methylated CpG islands are associated with the formation of 
nuclease-resistant chromatin and the DNA methyltransferases (DNMTs) are 
associated with histone deacetylases and histone methyltransferases, two key 
regulators of histone modification [19-21]. The levels of methylation and 
acetylation of specific lysine residues found in the tails of core histones of 
nucleosomes play a crucial role in regulating chromatin structure and gene 
expression [21]. Overall, histone hypermethylation and hypoacetylation are 
hallmarks of DNA regions that are methylated and repressed in normal cells like in 
the case of the inactive X chromosome in females, and silenced imprinted and 
tissue-specific genes.  
DNA methylation is a relatively stable epigenetic modification compared to 
most histone modifications. However, loss of DNA methylation, or DNA 
demethylation, has been observed in different biological contexts. This loss of 
methylation can occur in an active or passive fashion. Active DNA demethylation is 
an enzymatic process which facilitates the removal or modification of the methyl 
group from 5mC. In contrast, passive DNA demethylation refers to the loss of 5mC 
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during replication when functional DNA methylation maintenance machinery is 
absent [22]. Recently a series of discoveries have identified a family of DNA 
demethylases called Ten Eleven Translocation (TET), which can actively remove 
the 5mC mark from the CpG islands [23-26]. 
TET proteins were first discovered in a search of analogous DNA-modifying 
enzymes based on the analysis of Trypanosoma brucei base J-binding protein 1 (JBP1) 
[24], a dioxygenase that hydroxylates thymine in DNA [27]. The mammalian TET 
family consists of three members: TET1, TET2, and TET3 [28] which can convert 5mC 
to 5hmC. Recent studies have shown that TET enzymes can further oxidize 5hmC to 5-
formylcytosine (5fC) and 5-carboxylcytosine (5caC) in DNA [29]; [30]. All TET 
enzymes belong to 2-oxoglutarate (2-OG) and Fe(II)-dependent dioxygenase 
superfamily which is characterized by a C-terminal catalytic domain (CD). 5caC, which 
is an oxidation product of 5mC, can be further excised by thymine-DNA glycosylase 
(TDG) and replaced by unmodified cytosine through the base excision repair (BER) 
pathway [29]. 
Every 2OG-dependent oxygenase characterized to date requires Fe(II) for 
catalysis and oxidize the primary substrate (e.g. 5mC into 5hmC) with coupled 
oxidation of 2OG cosubstrate into succinate and CO2. During this process one atom of 
oxygen gets incorporated into the carboxylic acid group of succinate, while the fate of 
the other oxygen atom of dioxygen molecule depends on the type of oxidation reaction 
catalyzed. In the case of dehydration and desaturation reactions, the other oxygen is 
assimilated into water. However, in epoxidation and hydroxylation reactions, 
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incorporation of oxygen occurs into the epoxide or alcohol products, respectively. Since 
these oxygenases incorporate both the atoms of molecular oxygen into the products (e.g. 
succinate and 5hmC), they are also known as dioxygenases (Figure 2). 
To date two Fe(II), 2OG-dependent dioxygenase superfamilies catalyzing the 
oxidative modifications of nucleic acid bases have been identified; the AlkB- and the 
TET/JBP-family. The AlkB-family dioxygenases protect E. coli against the cytotoxic 
effects of methylating substances by directly dealkylating bases (1mA, 3mC, 1mG and 
3mT) in DNA [31, 32]. In humans, at least nine potential homologues of E. coli AlkB 
have been identified. Interestingly, similar to E. coli AlkB, some human homologs (e.g. 
ABH3 and FTO) can efficiently demethylate bases in single-stranded DNAs (ssDNA) 
and RNAs along with double-stranded DNA (dsDNA) [33, 34]. It is not known whether 
the TET-family of dioxygenases prefer 5mC demethylation in dsDNAs, ssDNAs or 
even in RNAs. Interestingly, 5mC is also a major RNA modification without much 
known functional significance [35]. 
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Figure 2 An overview of Fe(II), 2OG-dependent dioxygenases mediated oxidation of 
substrates involved in epigenetic regulation via a reactive oxo-ferryl [Fe(IV)=O] 
intermediate.  
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Bisulfide sequencing revealed that: (i) TET1-mediated 5mC demethylation is 
coupled with transcription because analysis of promoter truncated, transcriptionally 
inactive construct showed significantly less demethylation; (ii) demethylation is highly 
selective with few DNA strands being extensively demethylated while others are barely 
demethylated; (iii) of the two DNA strands in the transcribed region, 5mC 
demethylation is much more efficient on the non-transcribed (sense) strand than on the 
transcribed (antisense) strand [30]. All these observations suggest that the lax substrate 
specificity of TET1 is regulated by its interacting proteins which target it to specific 
sites of transcription initiation/elongation complexes. 
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Figure 3: A catalytic cycle of Fe(II), 2OG-dependent dioxygenases showing sequential 
binding of the cofactors and substrates leading to the formation of reactive oxo-ferryl 
[Fe(IV)=O] intermediate. The two histidines and one aspartate residues, which form the 
active site core, are called the 2-His-1-carboxylate facial triad. The conversion of 5mC 
to 5caC is mediated by three iterative catalytic/oxidation cycles by the TET family of 
dioxygenases generating 5hmC and 5fC as intermediates. 
Using a number of techniques, a detailed catalytic mechanism of Fe(II), 2OG-
dependent dioxygenases has been proposed (Figure 3) [36]. The TET-family 
dioxygenases convert 5mC into 5hmC, 5-formylcytosine (5fC) and 5-carboxylcytosine 
(5caC) by iterative oxidation steps [29]. Demethylation of 5mC takes place by the 
excision of 5caC, the final product in the TET-mediated oxidation reaction, by thymine-
DNA glycosylase, a base excision repair enzyme [29]. It seems that TET dioxygenases 
prefer 5mC as substrate over 5hmC and 5fC [37], which could possibly explain the low 
genomic level of 5fC and 5caC compared to 5hmC [29, 37]. It is interesting to note that 
during the first and third TET-mediated oxidation reactions (from 5mC to 5hmC and 
then from 5fC to 5caC), the oxo-ferryl intermediate possibly abstracts a hydrogen atom 
from the substrates (e.g. 5mC and 5fC) and then hydroxylates it in a rebound 
mechanism. While during the conversion of 5hmC into 5fC, the second TET-mediated 
oxidation reaction, hydroxylation is proceeded by a dehydration reaction producing 
water and 5fC. Thus TET enzymes are the first example of a bifunctional Fe(II), 2OG-
dependent dioxygenase in the mammalian system.	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Histone acetylation and deacetylation  
Chromatin immunoprecipitation assays performed with antibodies that are 
selective for hyperacetylated histones, demonstrated presence of high density of 
acetylated histones in regions correlating with general DNase I sensitivity. This fits well 
with transcriptional competence, as sensitivity to nuclease digestion and histone 
acetylation are often considered as salient features of chromatin accessible for 
transcription.  
Acetylation on histone is observed on lysine residues. DNA, owing to its high 
negative charge, associates with positively charged side chains of amino acids like 
lysine and arginine to form a compact structure. Acetylation of these residues results in 
loss of this charge – charge interaction between histone tail amino acids and DNA, 
resulting in weakened histone:DNA contacts. This altered state of histone tails can 
modulate the interactions between the adjacent nucleosomes. Also, changes in the 
nucleosome structure could affect the binding ability of other regulatory proteins, thus 
modulating chromatin structure. Taken together, alteration of the charge on the histone 
tail by the addition or removal of acetyl group could influence the structure of the 
individual nucleosome and also its higher order folding. These changes regulate the 
presence of an open or closed chromatin structure for transcription. In the last decade, 
several classes of enzymes have been identified which can add an acetyl group and ones 
that can remove this acetyl group. These discoveries have facilitated better 
understanding of chromatin dependent regulation of gene expression. 
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Histone methylation and demethylation 
Modulation of chromatin structure through covalent histone modification is 
one of the fundamental ways of regulating DNA accessibility during processes such 
as gene transcription, DNA replication and DNA damage repair. Methylation of 
histones can be done on either arginine or lysine residues [38-41]. On the lysine 
residue, ε-nitrogen undergoes methylation by either the SET domain- or non-SET 
domain containing lysine histone methyltransferases (PKMTs). As shown in the 
Figure 4, lysine residue could be modified by the addition of up to three methyl 
groups at each lysine producing a total of four methyl states: unmethylated, 
monomethylated, dimethylated or trimethylated. However, an arginine residue in 
histone proteins can only be mono- or dimethylated and this could be in either 
symmetric or asymmetric configuration. 
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Figure 4: Methylation of lysine and arginine residues by PKMTs 
For a long time it was believed that methylation of histone proteins on their 
lysine and arginine residues was a static modification. However, three distinct 
classes of enzymes with an ability to remove the methylation mark were eventually 
identified. PADI4 (Petidylarginine deiminase 4), the first enzyme identified 
converts methyl arginine into citrulline through a deimination reaction. In 2001, 
LSD1 (lysine specific demethylase 1), a histone lysine demethylase, was identified 
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and can remove methyl marks form H3-K4 and H3-K9 residues (mono or 
dimethylation) [42-44]. LSD1 catalysed through an oxidative demethylation 
reaction involving flavin as a cofactor. Other proteins like CoREST complex are 
necessary for full enzymatic activity, indicating involvement of regulatory subunits 
for modulation of their demethylase activity. A third class of enzymes containing a 
putative Jmj domain was identified, with various histone variants being the only 
known substrates. These Jmj domain-containing histone demethylases catalyzed 
demethylation of histone lysine residues through an oxidation reaction involving 
iron (II) and 2-oxoglutarate as cofactors. In humans ~25-30 putative Jmj domain 
containing histone demethylases (KDMs) have been identified and classified into 
seven families based on sequence similarities [45, 46]. 
  With the identification of KDMs and the dynamic nature of methylation, the 
effects of histone methylation on gene expression were shown to be site specific. 
Both activation and inhibition of gene expression by methylation of specific lysine 
residue has been observed. For example, methylation of the H3-K4 residue signifies 
presence of an open/active chromatin structure and H3-K27 signifies presence of 
closed/inactive form. The observed distribution patterns for H3K4me3, H3K27me3 
underlie the existence of diverse cellular states with varying gene expression 
profiles. This variation among cell types facilitates pluripotency and lineage 
differentiation. As epigenetic regulation of gene expression via histone modification 
plays a key role in determining cell fate, it is believed that it may help establish the 
tumour-initiating cell population early in tumorigenesis. Several studies have shown 
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existence of altered global histone modification patterns in several types of cancer, 
providing evidence for the role of epigenetic landscape and cellular context in 
tumorigenesis. 
 The enzymatic machinery involved in histone methylation 
Methylation of histone proteins was known to exist for many decades, but the 
significance of this modification and its role in modulation of chromatin structure and 
thus gene expression were not understood. A methyl group is added to either specific 
lysine or arginine residues on histone proteins, where SAM acts as a methyl donor. The 
enzymes associated with methylation of histone proteins are known as Histone 
methyltransferases and are classified into three classes, lysine-specific SET domain-
containing histone methyltransferases (PKMTs) involved in methylation of lysines 4, 9, 
27, and 36 of histone H3 and lysine 20 of histone H4; non-SET domain-containing 
lysine methyltransferases involved in methylating lysine 79 of histone H3; and arginine 
methyltransferases involved in methylating arginine 2, 17, and 26 of histone H3 as well 
as arginine 3 of histone H4 [47]. The SET domain in PKMTs is ≈130 amino acids and is 
highly conserved [48]. It also contains a Pre and Post SET domain, and forms a 
characteristic β fold, which constitutes the pseudoknot structure. This pseudoknot 
structure incorporates the two most conserved sequence motifs of SET domain 
(RFINHXCXPN and ELXFDY) to form a catalytically active site next to the methyl 
donor and peptide-binding cleft. Molecular dynamics studies of the enzyme substrate 
interactions gave clues about the mechanism of these enzymes. Each methylation step 
includes the formation of a water channel to allow proton dissociation from protonated 
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charged lysine into solvent (step 1), methylation of a neutral lysine by +AdoMet (step 
2), and product formation (step 3) [49]. These SET domain containing PKMTs can be 
classified into seven families; SUV39 family, SET 1 family, SET 2 family, RIZ family, 
SMYD family, EZ family, and SUV4-20 family based on the sequence surrounding 
their SET domain.  
Reaction mechanism and substrate specificity of histone demethylases 
The JmjC domain containing KDMs are members of non-heme iron (II)-
dependent dioxygenases that require molecular oxygen and 2-oxoglutarate (2OG) for 
catalysis. The reported crystal structures of 2OG-dependent dioxygenases [50, 51] have 
demonstrated the emergence of a common structural motif called the “2-His-1-
carboxylate facial triad” [52]. These structures reveal a β-strand core containing eight 
sheets folded into a distorted “jelly-roll” motif with an active site containing two 
histidine and a carboxylate ligands [53], occupying one face of the iron(II) coordination 
sphere. Of the remaining three sites of the iron(II) coordinate, the carboxyl and keto 
oxygens of the 2OG bind to the metal centre in bidentate manner. Whereas, the last site 
is occupied by O2, trans to any one of the three ligands of the 2-His-1-carboxylate facial 
triad. The 5-carboxylate group of 2OG binds to either arginine (present on the eighth β-
sheet of the “Jelly-roll”) or lysine (present on the fourth β-sheet of the “Jelly-roll”) 
residue from the enzyme (Figure 5). 
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Figure 5: A conserved active site structures of PAHX and JMJD2A derived from their 
crystal structures. The 5 carboxylate group of 2OG binds either arginine, as in PAHX, 
or lysine, as in JMJD2A. 
The demethylation proceeds in two steps. In the first step, these enzymes 
directly hydroxylate the affected methyl group of the substrate (e.g. H3-K9me3). In 
the second step, which does not require dioxygenase activity, formaldehyde is 
spontaneously released from hydroxylated methyl group to generate dimethylated 
product (e.g. H3-K9me2). In all 2OG-dependent dioxygenase reactions, the 
oxidation of the prime substrate is coupled to the conversion of 2OG into succinate 
and CO2. One of the oxygen atoms of the dioxygen is incorporated into the carboxyl 
group of succinate while, in the case of hydroxylation reactions, the other oxygen 
atom is incorporated into an alcohol product [10] (Figure 6) 
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Figure 6: Reaction scheme showing formation of dimethylated product from H3-K9me3 
by JMJD2A-C KDMs. 
General introduction to hypoxia 
Oxygen is an essential element for the survival of an aerobic organism. Oxygen 
acts as the final acceptor of electrons in the mitochondrial respiratory chain which is 
essential in the generation of cellular energy, in the form of adenosine triphosphate 
(ATP). ATP is essential for maintaining cellular viability. In a normoxic cell, there is 
abundance of oxygen which facilitates maintenance of a high and constant ratio of 
cellular ATP/ADP essential for the survival of the cell. This need for a high and 
constant ATP/ADP ratio highlights the dependence of the cell on oxygen. Any drop in 
then normal oxygen supply triggers hypoxia and alters cellular processes [54, 55].  
Hypoxia is experienced in many physiological processes (such as wound 
healing, embryonic development, etc., ) and also in patho-physiological conditions, 
such as obstructive sleep apnea, atherosclerosis, ischemic diseases (stroke), mountain 
sickness, retinal diseases, and cancer [56, 57]. Tissues and cells experiencing lower than 
normal oxygen tension could be due to reduced oxygenation of the blood (hypoxemia), 
a decrease in the oxygen supply sufficient to impair cellular function (hypoxia) and a 
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combination of hypoxia and lowered blood flow to the tissue/cells (Hypoxia-ischemia) 
[58, 59].  
Further response to hypoxia can be differentiated based on the duration of 
exposure into an acute, intermediate, and a chronic response; based on levels of oxygen 
concentration into a moderate (5-8% O2) and an anoxic level (<1 O2) (normoxia is 21% 
O2) [56, 60]. 
Hypoxia inducible factor (HIF) is a central molecule that plays a vital role in 
eliciting the effect of oxygen tension at the cellular level by modulating gene expression 
[61]. HIF-1α was originally identified while studying the human EPO gene, which 
encodes the glycoprotein hormone erythropoietin that regulates erythrocyte production 
[61]. DNA affinity purification assays revealed that HIF is a heterodimer consisting of 
HIF-1α and HIF-1β subunits [62, 63]. Also, HIF-1α protein levels increase as the O2 
concentration lowers [64]. Homology based search using HIF-1α sequence identified 
HIF-2α, which can also dimerize with HIF-β and initiate transcription by binding to the 
same recognition motif as HIF-1α [65]. HIF-1α (and HIF-2α) protein stability is 
negatively regulated by hydroxylation mediated by iron(II), 2-OG dependent prolyl 
hydroxylase domain protein (PHD). This hydroxylation of the HIFα isoforms leads to 
recognition and ubiquitination by E3 ubiquitin ligase von Hippel–Lindau protein (VHL) 
and targeting to proteasome-dependent degradation under normoxic conditions (9–11). 
Also, the transactivation ability of HIF-1α (and HIF-2α) is negatively regulated by 
factor inhibiting HIF-1 (FIH-1) in the nucleus [66]. FIH-1-dependent asparaginyl 
hydroxylation hinders the association of the coactivators CBP (CREB-binding protein) 
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and p300 with the HIF heterodimer [67, 68]. Thus, the stability and activity of the HIFs 
are regulated via their hydroxylation in an O2 dependent manner, thereby transducing 
the changes in O2 availability to changes in transcriptional activity of the cell. 
Epigenetic modulators induced by hypoxia 
As discussed histone lysine demethylase are classified into two classes, 
LSD1 and JmjC domain-containing KDMs. LSD1 is a flavin dependent enzyme, 
while most JmjC domain-containing histone demethylases are dioxygenases and are 
similar to FIH1, whose activities require Fe(II), α-ketoglutarate, and oxygen. As a 
result of this there is a possibility that their enzyme activities are affected by oxygen 
tension. In addition, recent studies have demonstrated that JMJD1A and JMJD2B 
are HIF targets, and other JmjC domain-containing proteins may also be upregulated 
by hypoxia or HIF [69-72]. Seven additional JmjC domain-containing proteins, 
including JMJD1B, JMJD2C, JMJD6, PLU-1, SMCX, RBP2, and KIAA1718 could 
be regulated by hypoxia. A chromatin immunoprecipitation (ChIP) sequencing 
approach also found 17 out of 22 JmjC family KDM genes upregulated under 
hypoxic conditions, with four (including PLU-1, JMJD1A, JMJD2B, JMJD2C) 
being direct HIF-1 targets [69]. It is still not clear what is the role of these KDMs in 
the hypoxic response and warranted more work in this area. Expression of the 
recently identified TET2 family of DNA demethylases has also been found to be 
modulated under hypoxia in cells originating from various tissues. These findings 
suggest a possible mechanism associated with regulating the expression of HIF 
target genes under hypoxic conditions via these epigenetic modulators.  
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CHAPTER II 
ENZYMATIC CHARACTERIZATION OF JMJD2 (JUMONJI DOMAIN 
CONTAINING) FAMILY OF HISTONE DEMETHYLASES 
Introduction 
Epigenetic mechanisms which govern cell fate and identity are regulated by 
histone modifying enzymes. Eukaryotic histone proteins undergo extensive 
modifications which constitutes the ‘histone code’ [2]. This controls the accessibility 
and usage of genetic information. Covalent histone modifications, specifically 
acetylation and methylation, play a major role in scripting the ‘histone code’. Histones 
are methylated on lysine or arginine residues. The predominant sites of lysine 
methylation are H3-K4, -9, -27, -36, -79 and H4K20 [2]. The SET domain containing 
protein lysine methyltransferases (PKMTs) methylate histone and non-histone proteins. 
Most histone methylating enzymes perform mono-, di- or trimethylation of the lysine 
side chain [73]. The SET domain in these enzymes is ≈130 amino acids. They also 
contain a Pre and Post SET domain, and form a characteristic β fold, which constitutes 
the pseudoknot structure [48]. This pseudoknot structure incorporates the two most-
conserved sequence motifs of the SET domain (RFINHXCXPN and ELXFDY) to form 
a catalytically active site next to the methyl donor and peptide-binding cleft. 
In the active site of PKMTs, the substrate and the cofactor (S-
adenosylmethionine / +AdoMet) bind at two adjacent sites of the conserved SET 
domain. The +AdoMet methyl group approaches the target lysine of the substrate to 
form Enz-LysNH3+·+AdoMet complex. The Enz-LysNH3+ [or Enz-LysN(Me)H2+ or 
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Enz-LysN(Me)2H+] must be deprotonated before methylation because only a neutral 
LysNH2 [or LysN(Me)H or LysN(Me)2] can be methylated by the +AdoMet cofactor.  
 
Figure 7: Catalytic scheme of SET domain containing lysine methyltransferases 
showing the formation of water channels. 
Molecular dynamics simulations of a number of Enz-LysNH3+·+AdoMet 
complexes suggest the formation of a water channel after the establishment of the 
complex (e.g. G9a-Lys9NH3+·+AdoMet). This water channel allows proton transfer 
from the protonated substrate to the solvent. Methyl transfer does not occur if a water 
channel is not formed. The number of accessible water channels determines whether a 
22 
 
PKMT transfers one, two, or three methyl groups to target lysine residue. Thus each 
methylation step includes the formation of a water channel to allow proton dissociation 
from protonated charged lysine into solvent (step 1), methylation of a neutral lysine by 
+AdoMet (step 2), and product formation (step 3) (Figure 7) [49]. 
LSD1, the first histone lysine demethylase (KDM) identified, can demethylate 
mono- and dimethylated H3-K4 and H3-K9 residues [43]. More recently, a number of 
Jumonji (Jmj) domain containing KDMs have been identified which can also 
demethylate trimethylated lysine residues of histone tails [44, 46, 74, 75]. The Jmj 
domain containing KDMs are members of non-heme iron (II)-dependent dioxygenases 
that require molecular oxygen and 2OG for catalysis. The demethylation proceeds in 
two steps; in the first step (enzyme-dependent), JmjD2 members directly hydroxylate 
the affected methyl group of H3-K9me3. In the second step (enzyme-independent), 
which does not require dioxygenase activity, formaldehyde is spontaneously released 
from the hydroxylated methyl group to generate H3-K9me2 (Figure 6).  
In light of the spectroscopic data [76, 77] and crystallographic studies [50, 78-
85], a detailed catalytic mechanism of the 2OG-dependent enzymes has been proposed 
(Figure 8). Stoichiometric binding of iron (II) to apoenzyme forms a distorted six 
coordinate octahedral ferrous active site (step 1). The affinity of 2OG binding is higher 
when iron (II) is present in the active site and results in a strong direct bidentate 
interaction between 2OG and iron(II). The keto carboxylate moiety of 2OG becomes 
much more planar when 2OG binds to iron(II) producing a new six coordinate 
octahedral geometry (step 2). 
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Figure 8: Catalytic scheme of iron(II), 2OG-dependent dioxygenases showing the 
‘ferryl’ intermediate [Fe(III)-O., equivalent to FeIV=O] and the effect on substrate 
oxidation. The two histidines and one aspartate form the active site core called the “2-
His-1-carb  
The six coordinate iron(II) site is relatively unreactive toward O2, thus limiting 
the rate of the uncoupled conversion of 2OG to succinate and CO2 in the absence of a 
substrate. Substrate binding, with 2OG present in the active site, dramatically changes 
the spectra of the iron site, indicating the formation of a square-pyramidal five 
coordinate species creating an open iron(II) coordinate site for O2 to bind (step 3). The 
fact that the open coordination position at the iron (II) site becomes available only when 
both substrate and cosubstrate are present supplies a critical coupling mechanism for the 
decarboxylation of 2OG and hydroxylation of the substrate. Dioxygen then reacts at the 
open coordination position of the five coordinate iron (II). The partial electron transfer 
from iron (II) to O2, gives oxygen a superoxo radical anion character (O2–) (step 4). This 
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activates O2 for the nucleophilic attack on the keto-carbon of 2OG (step 5). The 
resulting bridged intermediate then undergoes a concerted decarboxylation of 2OG and 
a heterolytic cleavage of the O-O bond, forming an oxo-ferryl [FeIV=O] intermediate 
(step 6). The oxo-ferryl intermediate abstracts a hydrogen atom from the substrate and 
then hydroxylates it in a rebound mechanism with significant exchange of oxygen from 
water [86], thus generating the product. 
In humans ~25-30 putative Jmj domain containing KDMs have been identified 
with various histone variants being the only known substrates [46, 75]. The JmjC 
domain containing KDMs have been classified into 7 families based on their sequence. 
The Jumonji domain-2 (JMJD2) family consist of four members, JMJD2A-D, and 
demethylates the trimethylated histone H3-lysine-9 (H3-K9me3), and also H3-K9me2 
and H3-K36me3 residues, albeit at lower rates [87]. JMJD2A-C are closely related 
isoforms with JMJD2D being the distinct one based on sequence homology. JMJD2A-C 
comprise an N-terminal catalytic core composed of JmjC and JmjN domains, a linker 
region, and a C-terminal region containing two PHD and Tudor domains.  
We believed that JMJD2 family of enzymes may have additional non-histone 
substrates because of the following three reasons. First, in the proposed reaction 
mechanism of iron (II), 2OG-dependent dioxygenases, substrate is not directly involved 
in generating the reactive oxo–ferryl intermediate (Figure 8).  
Consequently, the iron(II), 2OG-dependent dioxygenases generally have lax 
substrate specificity [88-90]. Second, a substrate profile of histone lysine 
methyltransferase G9a (which catalyzes the formation of H3-K9me1 and H3-K9me2, as 
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well as H3-K9me3 at a lower rate) identified a number of non-histone substrates [91]. 
This suggests the possibility for the existence of demethylases which can reverse 
methylation marks from non-histone proteins. Finally, the crystal structure of JMJD2A 
revealed that the binding of the methylated peptide substrates to the active site is 
achieved by few polar side chain interactions [50]. This provides a degree of plasticity 
in substrate recognition by JMJD2 family KDMs, an unusual feature for sequence 
specific enzymes. 
Therefore, in the first part of the current study we investigated if JMJD2A-C can 
accept peptides from non-histone proteins as substrates and demonstrated that these can 
indeed demethylate alternate peptide substrates (WIZ-K305me3, CDYL1-K135me3, 
CSB-K170me3, CSB-K297me3, CSB-K448me3, CSB-K1054me3 and G9a-K185me3, 
automethylation site of G9a) from four different proteins (WIZ, CDYL1, CSB and 
G9a). Surprisingly, all the non-histone substrates are components of transcription 
complexes. In the second part of the study, in order to determine the essential amino 
acids required for the identification of substrates by the Jmjd2a-c KDMs we searched 
for the existence of a consensus motif in these eight peptides (one histone and seven 
non-histones). These studies suggested preference for a smaller amino acid at –2 
position and conservation of Arg at the  –1 position (the methylated lysine is used as 
reference position 0 for amino acid numbering throughout the text). However, the 
conservation of Arg at the  –1 position may be due to G9a (H3-K9 methyltransferase) 
substrate specificity rather than Jmjd2 KDMs because all the non-histone substrates 
examined were G9a substrates [92]. In this study we identified the role of –1 and –2 
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residues in the substrate recognition by Jmjd2a-c KDMs. Surprisingly we also found 
similarities in the substrate specificities of G9a PKMT and Jmjd2a-c KDMs, although 
both the enzymes have different reaction mechanisms and structure. 
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Materials and Methods 
Cloning and expression of JMJD2A, JMJD2B, and JMJD2C (GASC1) 
Human cDNA clones of all three genes were used as the template for PCR. The 
N-terminal catalytic cores (1-349 amino acids) were amplified using the following 
primers: 5’-JMJD2A-SphI, SalI, SmaI, BamHI: 5’-
ACTAGTGTCGACACCCGGGAGGATCCCTGGAAGTTCTGTTCCAGGGGCCC 
ATGGCTTCTGAGTCTGAAAC-3’, 3’-JMJD2A-NotI, NdeI, HindIII, PstI: 5’-
CTGCAGAAGCTTCATATGGCGGCCGCCTATTCTGGCGTGGGCAG-3’, 
 5’-JMJD2B-SalI, KpnI: 5’-GTCGACGGGGTACCCTGGAAGTTCTGTTCCAGGG 
GCCCATGGGGTCTGAGGACCAC-3’, 3’-JMJD2B-NotI, XhoI: 5’-
CTCGAGGCGGCCGCTTACGCCGTGGGCCGCGT-3’, 5’-JMJD2C-XhoI, SalI, 
SmaI, BamHI: 5’-CTCGAGGTCGACACCCGGGGGGATCCCTGGAAGTTCTGTTC 
CAGGGGCCCATGGAGGTGGCCGAGGTG-3’ and 3’-JMJD2C-NotI, HindIII, PstI: 
5’-CTGCAGAAGCTTGCGGCCGCCTAAGTAGGCTTCGTGTGATC-3’. The 
amplified DNA sequences were gel purified and cloned into pGEM®-T vector 
(Promega, Madison, WI). The sequences of JMJD2A-C genes were verified by DNA 
sequencing using SP6 and T7 promoter primers. The verified genes were subcloned into 
pGEX-4T1 vector (GE Healthcare, Piscataway, New Jersey). The JMJD2A and 
JMJD2C were cloned using BamHI / NotI restriction sites, while SalI / NotI sites were 
used for JMJD2B. The recombinant vectors were transformed into E. coli BL21(DE3) 
cells for protein expression. Cells were grown in Luria-Bertani broth containing 100 
µg/ml ampicillin at 37°C, until the O.D.600 of the culture reached 0.8. The optimized 
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condition for recombinant protein expression was found to be 0.25 mM IPTG induction 
of bacterial culture (O.D.600 = 0.8) for 4 hrs at 37ºC. All three JMJD2 isoforms were 
produced at ~10% of the total soluble protein observed using 12% SDS-PAGE analyses. 
Protein purification 
All three recombinant JMJD2 protein isoforms were purified from 12 liter of 
culture. Bacterial cells were pelleted and either stored at –80°C or lysed immediately for 
protein purification. This step onwards all the steps of protein purification were 
performed on ice. The cells were resuspended in 30 ml of lysis buffer (PBS-10 mM 
Na2HPO4, 1.8 mM KH2PO4, 2.7 mM KCl, 140 mM NaCl, pH 7.3 containing 10% 
glycerol) and sonicated at an intensity of 5 for 6 mins with 6 pulses every 30 seconds 
(Sonic Dismembrator 550, Fisher Scientific). The lysate was spun down at 15,000 rpm 
for 20 min (Beckman J2-HS centrifuge) and the supernatant was collected and filtered 
through 0.45µ filter. Glutathione Agarose 4B resin (USB, Cleveland, Ohio) was used 
for purification of GST tagged proteins. The resin (100 ml) was packed into a XK50 
FPLC column (Pharmacia now GE Healthcare, Piscataway, New Jersey) and 
equilibrated in 10 bed volumes of wash buffer (PBS-10 mM Na2HPO4, 1.8 mM 
KH2PO4, 2.7 mM KCl, 140 mM NaCl, pH 7.3) using an  Akta FPLC system 
(Pharmacia/GE Healthcare). A constant flow rate of 1 ml/min was used for all steps. 
Clarified cell lysate was loaded onto the column and washed with the wash buffer (~ 
300 ml) till the flow through was clear. Elution of the bound protein was carried out 
using a gradient from the wash buffer to the elution buffer (50 mM Tris-HCl, 20 mM 
Glutathione, pH 7.5). 0 to 50% of elution buffer was reached in 60 min, followed by 
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holding at 50% elution buffer for 90 min and then at 0% elution buffer for 30 min. 
Samples of cell lysate before and after column loading, along with all the elution 
fractions (30 ml each) were collected and analyzed by SDS-PAGE. Selected fractions 
containing the desired protein (fractions 3-5) were concentrated to 3 ml using an 
Amicon Ultrafiltration stir cell (Millipore, USA). Concentrated protein was dialyzed 
using 12-14 kDa cut off dialysis membrane in 100 mM NaCl, 50 mM Tris-HCl, pH 7.5 
for 6-8 hrs, to remove glutathione used during elution. After dialysis, 15% glycerol was 
added to the protein, and aliquotes were stored at –80°C. 
Synthesis and purification of trimethylated peptide substrates 
Peptides containing the trimethylated lysine residues at the specific sites (Table 
1) were custom synthesized (Abgent, San Diego, California). These peptides were 
purified using an Agilent Zorbax Eclipse XDB-C18 column (4.6 x 250 mm, 5 µm 
particles). Liquid chromatography (LC) used the following conditions: flow rate of 300 
µL/min, with a gradient of 100% solvent A (0.1% TFA in water) for 3 min, 0% to 100% 
of solvent B (0.1% TFA in 30:70 water:acetonitrile) in next 5 min, then 0% to 100% of 
solvent C (0.095% TFA in acetonitrile) in next 7 min, then 0% to 100% of solvent A in 
next 1 min followed by a linear gradient of 100% A for 5 min. Trimethylated peptide 
peaks were collected and concentrated using a freeze dryer.  
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Table 1: Sequences of the custom synthesized trimethylated peptide substrates used in 
the study. 
 
A second set of peptides (Table 2) were synthesized in house using an Apex 396 
peptide synthesizer (AAPPTec, Louisville, KY). Synthesis was performed with Wang 
resin at 75 mg scale using the standard Fmoc chemistry. Amino acid loaded resin was 
swelled in dimethylformamide (DMF) for 10 mins with shaking. The transient 
protecting groups were removed with 20% piperidine in DMF. The resin was washed 
with DMF to remove any residual piperidine, followed by activation with HCTU and 
DIEA for coupling of the next amino acid. This cycle was repeated 14 times, and 
finally, the peptides were cleaved off the resin using 88% TFA v/v, 5% water v/v, 2% 
triisopropylsilane v/v and 5% phenol w/v. Cleaved peptides were precipitated in cold 
ether and centrifuged. The pellet was air dried overnight and resuspended in either 
Protein name Peptide name Peptide sequence Position 
Histone H3-K9me3 KQTARK(me3)STGGKAPRK 4-18 
WIZ WIZ-K305me3 SPPPTARK(me3)MFPGLAA 298-312 
CDYL1 CDYL1-K135me3 TSPNNARK(me3)QISRSTN 128-142 
CSB CSB-K170me3 TSRDINRK(me3)LDSVKRQ 163-177 
CSB CSB-K297me3 CNKRAARK(me3)APAPVTP 290-304 
CSB CSB-K448me3 EGGGGGRK(me3)VGRYRDD 441-455 
CSB CSB-K1054me3 ADHDVPKRK(me3)KFPASN 1046-1060 
G9a G9a-K185me3 KVHRARK(me3)TMSKPGNG 179-193 
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water or water/acetonitrile mixture. Diluted samples were infused into mass 
spectrometer to confirm the synthesis of the desired peptides.  
Purification of these peptides was carried out on Shimazdu preparative HPLC 
system using Beckman ODS semi preparative column (10 mm X 150 mm, 5 µm 
particles). Liquid chromatography (LC) used the following conditions: flow rate of 
2000 µL/min, with a gradient of 100% solvent A (0.1% TFA in water) for 5 min, 0% to 
70% of solvent B (0.095% TFA in acetonitrile) in next 15 min, then 70% to 100% of 
solvent B in next 3 min, then 0% to 100% of solvent A and 0% of solvent B in next 2 
min, followed by a linear gradient of 100% A for 5 min. Multiple fractions were 
collected during the purification chromatography. All the fractions were analyzed on 
mass spectrometer by infusion. Fractions containing the desired peptide were pooled 
and concentrated by freeze drying, and was resuspended in 200 µl of millipore water.  
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Table 2: Sequences of trimethylated peptide substrates synthesized in the lab. 
 
Purity of the peptides was confirmed using LCMS analysis. LCMS analysis was 
carried out on an ABI 2000 Q-Trap mass spectrometer fitted with electro-spray 
ionization (ESI) source and interfaced to an Agilent 1100 series HPLC system equipped 
with a diode array detector. LCMS was performed using an Agilent Zorbax Eclipse 
XDB-C18 column (2.1 x 150 mm, 3.5 µm particles) with the conditions described 
Protein name Peptide name Peptide sequence Position 
Histone H3-K9me3 KQTARKSTGGKAPRK 4-18 
WIZ WIZ-K305me3 SPPPTARKMFPGLAA 298-312 
WIZ WIZ-R304A-K305me3 SPPPTAAKMFPGLAA 298-312 
WIZ WIZ-A303W-K305me3 SPPPTWRKMFPGLAA 298-312 
G9a G9a-K185me3 KVHRARKTMSKPGNG 179-193 
G9a G9a-R184A-K185me3 KVHRAAKTMSKPGNG 179-193 
G9a G9a-A183W-K185me3 KVHRWRKTMSKPGNG 179-193 
G9a 
G9a- R184A -A183W-
K185me3 
KVHRWAKTMSKPGNG 179-193 
DNMT1 Dnmt1-K70me3 DLETKLRKEELSEEG 63-77 
KLF 12 KLF12-K313me3 SESPDSRKRRIHRCDF 305-321 
ACINUS ACINUS-K654me3 RSASSNSRKSLSPGV 646-660 
HDAC HDAC1-K432me3 EEGEGGRKNSSNFKKA 425-440 
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above (TFA was replaced with formic acid for LCMS). Detection of ions by the mass 
spectrometer was performed in Q1 positive multiple ion mode. Source temperature was 
set at 300 ºC and ion spray voltage at 5500 V. The declustering potential (DP) and 
entrance potential (EP) were set at 70 and 9, respectively. 
Demethylation assay: 
All assays were performed in duplicate in 50 µl reaction volume with final 
concentrations of 500 µM FeSO4, 4 mM 2-oxoglutarate, 10 mM ascorbate, 50 mM Tris-
HCl, pH 7.5, and 22.5 µg of purified enzyme. 50 nmoles of trimethylated peptide 
substrates were used in the assay. The reactions were carried out at 22 °C for 4 hrs and 
stopped by adding 50 µl of 0.25 M EDTA. Half of the assay reaction (50 µl) was loaded 
on an Agilent Zorbax Eclipse XDB-C18 column (2.1 x 150 mm, 3.5 µm particles) and 
analyzed by a Shimadzu 2010C HPLC system, while of the remaining sample 40 µl was 
analyzed by the LCMS method described earlier. The specific activities 
(nmole/min/mg) of the enzymes were determined by the disappearance of substrates. 
This was done by converting % reduction in the substrate peak area into nmole using 
22.5 µg of enzyme for 240 min. 
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Results 
Cloning, expression and purification of JMJD2A-C 
Truncated human JMJD2A-C (tJMJD2A-C) consisting of the N-terminal 
catalytic cores (1-349 amino acids) were PCR amplified using the primers described in 
the methods section (Figure 9).  
 
Figure 9: PCR amplification of truncated JMJD2A-C (1-349 amino acids). M – 1 Kb 
ladder, Lanes 1-2 JMJD2A, 3-4 JMJD2B and 5-6 JMJD2C. 
The amplified product was subsequently cloned into pGEMT vector and verified 
by restriction digest and sequencing (Figure 10A). Verified gene fragments were 
transferred into pGEX4T-1 vector as described in methods section and confirmed by 
restriction digest (Figure 10B, 10C, and 10D). The target genes were expressed as GST-
fusion proteins in E. coli. All three isoforms were produced at ~10% of the total soluble 
protein by SDS-PAGE analysis (Figure 11). The fusion proteins were purified (>90% 
purity) using GST affinity chromatography. The total size of the GST-tagged JMJD2A-
C was found to be 67.3 kDa. 
 
1050 bp
M 1 2 3  4  5  6
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Figure 10: (A) Double digest of pGEMT-JMJD2A (Lanes 1-2) and pGEMT-JMJD2C 
(Lanes 4-5) clones with BamHI and NotI and pGEMt-JMJD2B (Lane 3) with SalI and 
NotI releasing 1050 bp insert. (B) Double digest of pGEX-4T1-JMJD2A with BamHI 
and NotI releasing 1050 bp JMJD2A insert. (C) Double digest of pGEX-4T1-JMJD2C 
with BamHI and NotI releasing 1050 bp JMJD2C insert. (D) Double digest of pGEX-
4T1-JMJD2B with SalI and NotI releasing 1050 bp JMJD2B insert. M stands for 1 Kb 
ladder in all the panels. 
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66 kDa
 
Figure 11: SDS-PAGE analysis of purified GST-tJMJD2A-C proteins. The total size of 
the GST-tagged proteins is 67.3 kDa as indicated by the arrow. 
 
 
 
  
37 
 
Peptide Synthesis and Purification 
Nine 15-mer peptides were synthesized at 75 mg scale using an Apex 396 
peptide synthesizer and purified as described in materials and method section. All the 
peptides synthesized were solubilized in either water or water/acetonitrile mixture. The 
peptide samples were loaded onto a preparative HPLC column as described in methods 
section and all fractions observed in the chromatogram were collected and analyzed by 
infusing into a mass spectrometer. Peaks corresponding to the desired peptides are 
identified in the individual chromatograms (Figure 12A-I). Purity of all the peptides 
was assessed to be ≥98% by LCMS analysis using an Agilent Zorbax Eclipse XDB-C18 
column (2.1 x 150 mm, 3.5 µm particles). In the purified peptides no peaks 
corresponding to di or monomethylated impurities were detected by LCMS analysis 
(Figure 13). 
 
Figure 12: Liquid chromatography profiles of synthesized non-histone peptides: A) 
Dnmt1-K70me3, B) KLF12-K313me3, C) ACINUS-K654me3, D) HDAC1-K432me3, 
E) G9a-R184A-K185me3, F) WIZ-R304A-K305me3, G) G9a-R184A-A183W-
K185me3, H) WIZ-A303W-K305me3 and I) G9a-A183W-K185me3.  
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Figure 13: LC-MS analysis of all the peptides used in the study: A) H3-K9me3, B) 
WIZ-K305me3, C) CDYL1-K135me3, D) CSB-K170me3, E)  CSB-K297me3, F) CSB-
K448me3, G) CSB-K1054me3, H) G9a-K185me3, I) Dnmt1-K70me3, J) KLF12-
K313me3, K) ACINUS-K654me3, L) HDAC1-K432me3, M) G9a-R184A-K185me3, 
N) WIZ-R304A-K305me3, O) G9a-R184A-A183W-K185me3, and P) WIZ-A303W-
K305me3. 
I
G9a-­‐A183W-­‐K185me3
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LCMS-based demethylase assay development 
The non-histone trimethylated peptides from widely interspaced zinc finger 
motifs protein (WIZ), chromodomain Y-like protein (CDYL1), Cockayne syndrome 
group B protein (CSB, four peptides) and G9a were custom synthesized (Table 1). In 
addition, a second set of peptides were synthesized and purified (Table 2). H3-K9me3 
peptide was used as a positive control. Next, a liquid chromatography (LC) method was 
developed using an Agilent Zorbax Eclipse XDB-C18 column (2.1 x 150 mm, 3.5 µm 
particles). This allowed separation and quantification of the substrate (H3-K9me3, 
eluted at 9.3 min) and the products (H3-K9me2, eluted at 11.6 min and H3-K9me1, 
eluted at 14.5 min). This LC method was used to identify optimized cofactor 
concentrations (500 µM FeSO4, 4 mM 2OG and 10 mM ascorbate). A time course 
experiment (0-4 hrs) was performed and assay duration was fixed to 4 hrs. 
 
Kinetic properties of JMJD2A-C with H3-K9me3 as substrate 
For uniformity the specific activities of JMJD2A-C were determined by 
reduction of substrate peak area because more than one product (di- and/or 
monomethylated products, ratios of which varied among different substrates and 
enzyme isoforms) was formed in the assay reactions. Specific activities, determined by 
the reduction of substrate peak area, were linear during the course of the reaction 
(Figure 14, Figure 15). 
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Figure 14 Plot of specific activity (nmole/min/mg) vs time (min) for JMJD2B with 
WIZ-K305me3. Note that WIZ-K305me3 showed linearity being the best substrate for 
JMJD2B. 
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Figure 15: Plot of specific activity (nmole/min/mg) vs time (min) for JMJD2C with 
WIZ-K305me3. Note that WIZ-K305me3 showed linearity being the second best 
substrate for JMJD2B. 
Although, JMJD2A, B and C isoforms share high sequence homology (Figure 
16), we observed differences in their specific activities with JMJD2A being the most 
active isoform (1.0 ±0.5 nmole min-1 mg-1) followed by JMJD2C (0.5 ±0.5 nmole min-1 
mg-1), while JMJD2B was the least active isoform (0.29 ±0.13 nmole min-1 mg-1) 
kcat/KM). The kcat/KM values were determined by dividing the specific activity (velocity, 
nmole min-1 mg-1) with total enzyme added (15 nmoles) and substrate (50 nmole/µl) and 
were found to be 1.1 M-1s-1for JMJD2A, 0.56 M-1s-1 for JMJD2C and 0.33 M-1s-1for 
JMJD2B. The observed specific activities are relatively low, which is not surprising 
given the drastic effect these enzymes exert on transcription [93, 94]. 
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Figure 16: Multiple sequence alignment of tJMJD2A-C proteins. Initial alignment was 
done using ClustalW and then manually adjusted for secondary structure prediction 
using Jnet server. Substrate (peptide backbone) binding domains are boxed in black, 
while methylated lysyl side-chain environment is in blue. The residues binding the 
catalytic iron(II) are in red and 2OG in orange. Predicted secondary structure elements 
are given below the alignment.  
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Identification of non-histone substrates: 
Next, we checked if JMJD2A-C can accept peptides from non-histone proteins 
as substrates. The trimethylated non-histone peptides from WIZ, CDYL1, CSB and G9a 
proteins were incubated with optimized cofactors in the presence and absence of 
JMJD2A-C. LC assays clearly showed appearance of a new peak consistent with the 
retention time of dimethylated peptide in the presence of enzyme (Figure 17). 
 
Figure 17: Liquid chromatography method used to characterize JMJD2 family KDMs. 
The left panel shows HPLC profile of CSB-K170me3 peptide in the absence of enzyme 
(negative control), while the right panel shows HPLC profile of CSB-K170me3 peptide 
in the presence of JMJD2A (assay reaction). 
Mass spectrometry analysis confirmed that the new peak was indeed of 
dimethylated peptide products (Figure 18). For some substrates peaks corresponding to 
monomethylated peptides were also detected in the presence of enzymes (Table 3). 
Interestingly, JMJD2A-C KDMs showed better activities with a number of non-histone 
substrates compared to its only known substrate, H3-K9me3 (Table 4).  
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Table 3: Identification of monomethylated products by LCMS method formed by 
demethylation of the corresponding trimethylated peptide substrates. A “+” indicates 
presence while “–” indicates absence of monomethylated peptide. 
 
Table 4: Specific activity of GST-tJMJD2A-C KDMs for histone (H3-K9me3) and non-
histone substrates. All values are nmole min-1 mg-1 
 
JMJD2A, JMJD2B and JMJD2C showed the best specific activities with G9a-
K185me3 (2.6 ±0.2 nmole min-1 mg-1), WIZ-K305me3 (3.5 ±0.4 nmole min-1 mg-1) and 
CDYL1-K135me3 (3.40 ±0.01 nmole min-1 mg-1), respectively. In general WIZ-
K305me3 was the best substrate and showed linear specific activities over the course of 
reaction (Figure 14, Figure 15). The activity pattern (JMJD2A>JMJD2C>JMJD2B) of 
only CSB-K1054me3 was similar to H3-K9me3. JMJD2B and 2C isoforms showed 
better activities than JMJD2A towards WIZ-K305me3, CSB-K170me3 and CSB-
Isoforms H3-
K9me3 
WIZ-
K305me3 
CDYL1-
K135me3 
CSB-
K170me3 
CSB-
K297me3 
CSB-
K448me3 
CSB-
K1054me3 
G9a-
K185me3 
tJMJD2A + – + – – + – – 
tJMJD2B – + + – – + + – 
tJMJD2C – + + – – + – – 
Isoforms H3-
K9me3 
WIZ-
K305me3 
CDYL1-
K135me3 
CSB-
K170me3 
CSB-
K297me3 
CSB-
K448me3 
CSB-
K1054me3 
G9a-
K185me3 
tJMJD2A 1.0 ±0.5 1.88 ±0.13 1.00 ±0.12 1.1 ±0.2 0.64 ±0.12 0.6 ±0.2 1.9 ±0.2 2.6 ±0.2 
tJMJD2B 0.29 ±0.13 3.5 ±0.4 0.95 ±0.07 2.0 ±0.4 0.4 ±0.3 2.5 ±1.1 1.43 ±0.13 2.4 ±0.6 
tJMJD2C 0.5 ±0.5 3.1 ±0.4 3.40 ±0.01 1.9 ±0.2 1.5 ±0.3 2.32 ±0.10 1.63 ±0.05 2.12 ±0.03 
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K448me3. While all three isoforms showed similar activities with G9a automethylation 
site (G9a-K185me3). 
 
Figure 18: Liquid chromatography method used to characterize JMJD2 family KDMEs. 
The bottom left panel shows HPLC profile of CSB-K170me3 peptide in the absence of 
enzyme (negative control), while the bottom right panel shows HPLC profile of CSB-
K170me3 peptide in the presence of JMJD2A (assay reaction). The upper three panels 
in both the negative control and assay reaction show mass scan for tri-, di- and 
monomethylated CSB-1 peptides. The assay reaction shows appearance of dimethylated 
product peak at 11.56 mins in LC with a corresponding MS peak at 11.76 mins. Peaks 
for di- and monomethylated peptides in the mass scans for negative control are due to 
fragmentation of the trimethylated peptide in MS. Similarly, dimethylated product lost 
one methyl group and was detected in the mass scan for monomethylated peptide in 
assay reaction.  
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Importance of Arginine at –1 position for substrate recognition by JMJD2 KDMs 
Based on the identification of seven non-histone peptide substrates (WIZ-
K305me3, CDYL1-K135me3, CSB-K170me3, CSB-K297me3, CSB-K448me3, CSB-
K1054me3 and G9a-K185me3) from four different proteins (WIZ, CDYL1, CSB and 
G9a)  as substrates for JMJD2a-c KDMs, we wanted to evaluate the substrate specificity 
of JMJD2A-C KDMs [92]. In order to determine essential amino acids required for 
substrate recognition by the Jmjd2a-c KDMs, we searched for consensus motifs in these 
eight peptides (one histone and seven non-histones). These studies suggested 
conservation of Arg at the –1 position. However, the conserved Arg at the –1 position 
may be due to G9a PKMT substrate specificity rather than Jmjd2 KDMs because all the 
non-histone substrates examined were G9a substrates [92]. Site-directed mutagenesis 
studies by Rathert et al. showed preference of Arg at –1 position for G9a substrate 
recognition [91]. Therefore, to study the role of Arg at –1 position for Jmjd2 substrate 
recognition we mutated –1 Arg to Ala in two most efficient non-histone substrates 
(WIZ and G9a) and performed demethylation assays with JMJD2a-c. While G9a-
R184A-K185me3 mutant showed ~60% reduction in the activity (e.g. the specific 
activity of GST-tJMJD2a was 1.54±0.3 nmoles min-1 mg-1 using G9a-K185me3 as 
substrate compared to 0.5±0.12 nmoles min-1 mg-1 for the G9a-R184A-K185me3 
mutant), there was a complete loss in the activity with WIZ-R304A-K305me3 mutant as 
substrate for all three isoforms of JMJD2 (Table 5, Figure 19,Figure 20, Figure 21). 
These experiments clearly demonstrate a critical role for Arg at –1 position in substrate 
recognition by JMJD2 family KDMs. 
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Figure 19: LCMS analysis showing the importance of Arg at –1 position in Jmjd2A 
substrates. The bottom left panel shows HPLC profile of WIZ-K305me3 peptide in the 
absence of enzyme (negative control), while the bottom right panel shows HPLC profile 
of WIZ-K305me3 peptide in the presence of JMJD2A (assay reaction). The top left 
panel shows HPLC profile of WIZ-R304A-K305me3 peptide in the absence of enzyme 
(negative control), while the top right panel shows HPLC profile of WIZ-R304A-
K305me3 peptide in the presence of JMJD2A (assay reaction). Note the absence of 
product in WIZ-R304A-K305me3 mutant.  
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Figure 20: Liquid chromatography method used to characterize JMJD2A-C KDMs. The 
bottom left panel shows HPLC profile of WIZ-K305me3 peptide in the absence of 
enzyme (negative control), while the bottom right panel shows HPLC profile of WIZ-
K305me3 peptide in the presence of JMJD2A (assay reaction). The upper two panels in 
both the negative control and assay reaction show mass scan for tri- and dimethylated 
WIZ-K305me3 peptides. The assay reaction shows appearance of dimethylated product 
peak at 12.01 min in LC with a corresponding MS peak at 12.36 min. Peaks for 
dimethylated peptides in the mass scans for negative control are due to fragmentation of 
the trimethylated peptide in MS.  
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Figure 21: Liquid chromatography method used to characterize JMJD2A-C KDMs. The 
bottom left panel shows HPLC profile of WIZ-R304A-K305me3 peptide in the absence 
of enzyme (negative control), while the bottom right panel shows HPLC profile of 
WIZ-R304A-K305me3 peptide in the presence of JMJD2A (assay reaction). The upper 
two panels in both the negative control and assay reaction show mass scan for tri- and 
dimethylated WIZ-R304A-K305me3 peptides. The assay reaction shows no 
dimethylated product peak in LC and no corresponding MS peak. Peaks for 
dimethylated peptides in the mass scans for negative control are due to fragmentation of 
the trimethylated peptide in MS.  
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Table 5 Specific activities of GST-tJMJD2A-C KDMs for H3-K9me3 and non-histone 
substrates (nmoles min-1 mg-1 ± SE). 
 
 
 
  
Peptide tJMJD2A tJMJD2B tJMJD2C 
H3-K9me3 2.32±0.23 1.98±0.19 2.32±0.42 
WIZ-K305me3 2.5±0.31 2.5±0.44 2.5±0.5 
WIZ-R304A-K305me3  0.06±0.01 -0.01±0.04 -0.09±0.04 
WIZ-A303W-K305me3  1.09±0.23 1.30±0.44 1.52±0.21 
G9a-K185me3 1.54±0.3 1.2±0.64 1.9±0.24 
G9a-R184A-K185me3  0.5±0.12 0.8±0.24 0.70±0.31 
G9a-A183W-K185me3 0.82±0.14 0.62±0.1 0.90±0.13 
G9a-A183W-R184A-K185me3 0.43±0.13 0.15±0.1 0.08±0.09 
Dnmt1-K70me3 0.2±0.06 0.24±0.12 0.11±0.08 
KLF12-K313me3 0.14±0.1 0.10±0.08 0.14±0.1 
ACINUS-K654me3 0.3±0.11 0.11±0.06 0.3±0.07 
HDAC1-K432me3 0.3±0.14 0.23±0.12 0.51±0.21 
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Preference of smaller amino acids at –2 position for substrate recognition by JMJD2 
KDMs 
Our motif search also suggested a preference for a smaller amino acid at the –2 
position. Ng et al. also suggested propensity for smaller amino acids at –2 position by 
aligning the sequences of H3-K9me3 and H3-K36me3 peptides (Ala-7 in H3-K9 and 
Gly-34 in H3-K36) [50]. To evaluate the role of smaller amino acids at –2 position, we 
synthesized WIZ and G9a peptides with an Ala to Trp substitution at –2 position. The 
demethylation assays with G9a-A183W-K185me3 and WIZ-A303W-K305me3 mutants 
showed up to 50% reduction in the specific activities for all three isoforms of JMJD2 
(2.5±0.31 for WIZ-K305me3 to 1.09±0.23 nmoles min-1 mg-1 for WIZ-A303W-
K305me3 mutant and 1.54±0.3 for G9a-K185me3 to 0.82±0.14 nmoles min-1 mg-1 for 
G9a-A183W-K185me3 mutant using GST-tJMJD2A KDM) (Table 5, Figure 22, Figure 
23, Figure 24). These results demonstrate that a smaller amino acid at –2 position is one 
of the important determining factors for substrate specificity by JMJD2 family KDMs. 
We also went ahead and synthesized a G9a peptide with mutations incorporated at -1 
(Arg to Ala) and -2 (Ala to Trp) positions. This resulted in further reduction in specific 
activity from 1.54±0.30 to 0.43±0.13 nmoles min-1 mg-1 for JMJD2A, 1.2±0.64 to 
0.15±0.1 nmoles min-1 mg-1 for JMJD2B and 1.9±0.24 to 0.08±0.09 nmoles min-1 mg-1 
for Jmjd2C. 
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Figure 22: LCMS analysis showing the importance of smaller amino acid at –2 position 
in JMJD2A substrates. The bottom left panel shows HPLC profile of G9a-K185me3 
peptide in the absence of enzyme (negative control), while the bottom right panel shows 
HPLC profile of G9a-K185me3 peptide in the presence of Jmjd2a (assay reaction). The 
top left panel shows HPLC profile of G9a-A183W-K185me3 peptide in the absence of 
enzyme (negative control), while the top right panel shows HPLC profile of G9a-
A183W-K185me3 peptide in the presence of Jmjd2a (assay reaction).  
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Figure 23: Liquid chromatography method used to characterize JMJD2A-C KDMs. The 
bottom left panel shows HPLC profile of G9a-K185me3 peptide in the absence of 
enzyme (negative control), while the bottom right panel shows HPLC profile of G9a-
K185me3 peptide in the presence of JMJD2A (assay reaction). The upper two panels in 
both the negative control and assay reaction show mass scan for tri- and dimethylated 
G9a-K185me3 peptides. The assay reaction shows appearance of dimethylated product 
peak at 12.06 min in LC with a corresponding MS peak at 12.31 min. Peaks for 
dimethylated peptides in the mass scans for negative control are due to fragmentation of 
the trimethylated peptide in MS. 
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Figure 24: Liquid chromatography method used to characterize JMJD2A-C KDMs. The 
bottom left panel shows HPLC profile of G9a-A183W-K185me3 peptide in the absence 
of enzyme (negative control), while the bottom right panel shows HPLC profile of G9a-
A183W-K185me3 peptide in the presence of JMJD2A (assay reaction). The upper two 
panels in both the negative control and assay reaction show mass scan for tri- and 
dimethylated G9a-A183W-K185me3 peptides. The assay reaction shows appearance of 
dimethylated product peak at 12.06 min in LC with a corresponding MS peak at 12.31 
min. Peaks for dimethylated peptides in the mass scans for negative control are due to 
fragmentation of the trimethylated peptide in MS. There is a clear reduction in product 
peak with G9a-A183W-K185me3 peptide compared to G9a-K185me3 wild type 
peptide.  
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Similarity in substrate specificities of G9a methyltransferase and Jmjd2 demethylases 
To gain further insight into substrate specificity of JMJD2 KDMs, four new 
non-histone methylated peptides from Dnmt1, KLF12, ACINUS and HDAC1 were 
synthesized. A previous study identified these peptides as poor substrates of G9a PKMT 
[91]. Interestingly, these non-histone methylated peptides also showed poor activity 
with all three isoforms of JMJD2 KDMs (Table 5) compared to the ones identified in 
Ponnaluri et al [92]. Among these newly synthesized non-histone substrates HDAC1-
K432me3 showed the highest activity (0.51±0.21 nmoles min-1 mg-1) compared to 
ACINUS-K654me3, KLF12-K313me3 and Dnmt1-K70me3 (0.3±0.07, 0.14±0.1 and 
0.11±0.08 nmoles min-1 mg-1, respectively, using GST-tJMJD2C). Interestingly, along 
with Arg at –1 position, only HDAC1-K432me3 has a smaller amino acid (Gly) at –2 
position; while ACINUS-K654me3, KLF12-K313me3 and Dnmt1-K70me3 have Leu, 
Ser and Asn, respectively, all larger amino acids (Table 2). These results further show 
that JMJD2A-C KDMs prefer a smaller amino acid at –2 position for substrate 
selectivity. 
G9a methylates histones and some non-histone proteins [91, 95]. Rathert et al. 
showed strong preference for Arg at –1 position for methylation by G9a [91]. This 
result correlates well with the crystallographic data [96], which identified interactions 
between the guanidino group of –1 Arg and the carboxyl groups of Asp1145, Asp1135, 
Asp1131 of G9a-like-protein (G9a-like-protein and G9a share >80% identity in their 
SET domain). These interactions help orient the substrate in the active site of G9a-like-
protein. Our results demonstrate that JMJD2A-C KDMs, which catalyze the opposite 
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reaction, also prefers Arg at –1 position. A closer examination of tJmjd2a structure, co-
crystallized with H3-K9me3 substrate [50], identified similar interactions between the 
guanidino group of –1 Arg from the substrate with the carboxyl group of Glu169 of  
tJmjd2a. 
The structures of a number of PKMTs have been reported [97-102]. These 
structures collectively highlight a remarkable plasticity in the substrate / peptide binding 
site and lack of clear structural motifs that correlate with sequence selectivity. Similarly, 
the crystal structure of JMJD2A revealed that the binding of the methylated peptide 
substrates to the active site are achieved by few polar side chain interactions [50]. This 
provides a degree of plasticity in substrate recognition by JMJD2 family KDMs, an 
unusual feature for sequence specific enzymes. Taken together, these results suggest 
that lysine methylating and demethylating enzymes are generally very non-specific with 
only a few amino acids (Arg at –1 position and a small amino acid –2 position) 
determining their substrate selectivity. This is very surprising considering these 
enzymes catalyze opposing reactions, have completely different structures and reaction 
mechanisms (supplementary text). A recent proteomics study identified 1750 proteins 
with 3600 unique acetylation sites [103] which are in good comparison to the number of 
phosphorylation sites found in the cell [104, 105]. Considering lax substrate 
specificities of protein lysine methylases and demethylases it is likely that, like 
acetylation and phosphorylation, methylation is a more prevalent post translational 
modification of cellular proteins than what is currently known. 
69 
 
Discussion 
JMJD2A-C KDMs demethylate trimethylated histone H3-lysine-9 (H3-K9me3), 
and also H3-K9me2 and H3-K36me3 albeit at lower rates. In the current study we 
expressed and purified JMJD2A-C isoforms to homogeneity. An LCMS method was 
developed to separate and quantify both substrate (trimethylated) and products (di- 
and/or monomethylated peptides). This method was used to determine the kinetics of 
the enzymes for both histone and non-histone substrates. We demonstrated for the first 
time that in addition to its only known substrate, H3-K9me3, JMJD2A-C can 
demethylate non-histone peptides from WIZ, CDYL1, CSB and G9a proteins. 
Interestingly, JMJD2A-C showed better activities with non-histone substrates identified 
in this study, suggesting they may have additional demethylation roles in vivo (Table 4). 
The crystal structure of JMJD2A in complex with H3-K9me3 and H3-K36me3 
peptides showed that the binding of these two substrates were achieved by distinct 
conformations, yet orientation of trimethylated lysine toward the active site were 
superimposable [50]. The preference of H3-K9me3 over H3-K36me3 by JMJD2A was 
due to intra-substrate hydrogen bonding and presence of a Gly-Gly motif at the +3 
position. However, a Gly-Gly motif was absent in WIZ-K305me3, CSB-K1054me3, 
and G9a-K185me3 peptides, which were significantly better substrates than H3-K9me3, 
suggesting a sequence specific requirement of this motif only in H3-K9me3 peptide for 
catalysis by JMJD2A. All the substrates examined in this study contain an Arg at –1 
position. This may be due to the candidate-based approached taken during this study. 
Since all the substrates examined in this study were substrates of G9a, preference of 
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Arg at –1 position could be due to G9a methyltransferase rather than JMJD2 
demethylases. Indeed, in H3-K36me3 peptide, which is also a substrate of JMJD2A, 
Arg is absent at –1 position suggesting lack of absolute requirement of this residue in 
the JMJD2A substrates. Ng et al. [50] suggested propensity for smaller amino acids in 
the –2 position by sequence alignment of H3-K9me3 and H3-K36me3 peptides (Ala-7 
in H3-K9 and Gly-34 in H3-K36). Consistently, in this study five of the seven non-
histone substrates carried either an Ala or a Gly residue at the –2 position. Taken 
together, these results suggest remarkable flexibility in the substrate recognition by 
JMJD2-family KDMs. 
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Conclusion 
Crystal structure of JMJD2A revealed that the binding of the methylated peptide 
substrates is achieved by few polar side chain interactions providing some degree of 
plasticity in substrate recognition [50]. JMJD2 family KDMs contains many protein-
protein interacting domains like PHD and Tudor domain. These domains are mainly 
found in nuclear proteins which are associated with transcriptional regulation. JMJD2 
family KDMs, which are overexpressed in a number of cancers, were believed to 
reverse the methylation marks on the lysine residue of histone tail. In prostate cancer, 
JMJD2-family KDMs are involved in androgen receptor (AR)-mediated upregulation of 
AR-response genes by reversion of the repressive H3-K9me3 mark [93, 94]. It is 
interesting to note that repressive heterochromatin formation is initiated by a complex 
consisting of G9a, WIZ, CtBP, GLP, and CDYL1 proteins. During this process WIZ 
stabilizes G9a/GLP heterodimer [106] and mediates its interaction with CtBP, allowing 
methylation of H3-K9 by G9a [107]. H3-K9me3 is recognized by chromodomain 
(methylated lysine binding domain) of CDYL1, initiating formation of local repressive 
chromatin structure [107] (Figure 25).  
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Figure 25: Model depicting the interaction observed in the transcription machinery 
associated with formation of the repressive heterochromatin. 
All the non-histone substrates identified in this study are involved in 
transcriptional regulation. Therefore, reversion of methylation marks on H3-K9 and 
G9a interacting proteins, as identified in this study, may allow upregulation of 
transcription by JMJD2 family KDMs during cancer development. Thus identification 
of these non-histone substrates for JMJD2A-C KDMs suggests presence of a new layer 
of epigenetic regulation. We also identified the importance of Arg at –1 position and a 
smaller amino acid at –2 position in the substrate specificity of Jmjd2 family KDMs. 
Although G9a PKMT and JMJD2A-C KDMs catalyze opposing reactions and have 
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completely different structures and reaction mechanisms, we found similarities in their 
substrate specificities. Based on our results and lax substrate specificities of methylases 
and demethylases, we believe that methylation is a much more prevalent post 
translational modification than currently known.  
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CHAPTER III 
EVALUATING THE ROLE OF HISTONE DEMETHYLASES IN OXYGEN 
MEDIATED PATHOPHYSIOLOGICAL CONDITIONS 
Introduction 
Oxygen plays a critical role as the electron acceptor during oxidative 
phosphorylation, a key process in cellular energy generation. In addition, oxygen also 
plays important roles in apoptosis, membrane transport [108], and gene expression 
[109]. Thus, it is essential to maintain oxygen homeostasis in cells. If the oxygen 
tension in our body drops below the threshold levels, cells experience hypoxia. Hypoxia 
is observed in both physiological as well as pathological conditions. Physiological 
processes where hypoxia is experienced include wound healing, embryonic 
development, and adaptation to higher altitudes. Pathological conditions include 
ischemic heart diseases, neovascularization in cancer and retinal diseases [110]. 
Hypoxia inducible factor (HIF) is a central molecule that plays a vital role in 
eliciting the effect of oxygen tension at the cellular level by modulating gene expression 
[61]. HIF is a member of PAS family of basic helix-loop-helix heterodimeric 
transcription factors, consisting of α subunits (HIF-1α, -2α, and -3α) and HIF-1β/ARNT 
subunit. Normally, hydroxylation of the conserved proline residues (Pro402 and Pro564 
in human HIF-1α) by the oxygen-dependent HIF prolyl hydroxylases/dioxygenases 
(PHD1-3) under normoxic conditions allows the binding of HIF-α isoforms to the wild-
type (wt)-pVHL. This binding of hydroxylated HIF-α to pVHL, the substrate 
recognition subunit of an E3 ubiquitin ligase, allows rapid proteosomal degradation of 
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HIF-α under normoxia [111, 112]. When the oxygen level drops, PHDs become inactive 
resulting in lower HIF-α prolyl-hydroxylation, allowing it to escape proteosomal 
degradation. Following this process, HIF-α translocates to the nucleus and dimerizes 
with HIF-β. Thus during hypoxia HIF-α/β heterodimer accumulates in the nucleus, 
recruits several transcriptional co-activators, and binds to hypoxia response element 
(HRE) of target genes causing overexpression of VEGF and other pro-angiogenic 
factors. 
HIF pathway is intimately associated with the pathobiology of a number of oxygen-
dependent retinal diseases such as VHL, proliferative diabetic retinopathy, glaucoma, 
and retinopathy of prematurity [113]. In all these conditions hypoxia-induced 
neovascularization is the central cause of pathogenesis. Little is known about the 
epigenetic regulation during HIF-mediated transcription activation of pro-angiogenic 
genes in oxygen-dependent retinal diseases. However, transcriptional adaptations 
mediated by hypoxia and HIFs (HIF-1α, HIF-2α, HIF3α and HIF-1β/ARNT) suggest 
changes in the epigenetic histone modifications [114]. A number of recent studies have 
identified a role of histone methylation in HIF-mediated hypoxia adaptation in cancer 
cell [69-71]. The HIF pathway upregulates, in addition to many known proteins that 
facilitate metabolic adaptation to hypoxia, transcription of 17 out of the 22 Jumonji-C 
(Jmj) domain containing iron (II), 2-oxoglutarate (2OG)-dependent histone lysine 
demethylases (KDMs) in the hypoxic cancer cells [69]. Of these 17, four Jmj KDMs 
(JMJD1A, JMJD2B, JMJD2C and JARID1B) were direct transcription targets of HIF as 
HIF-α/β bound to the HRE present in the promoter regions of these genes [69]. 
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JMJD1A regulates the expression of some pro-angiogenic hypoxia-inducible genes 
(ADM and GDF15) by decreasing histone methylation at their promoters and knock-
down of JMJD1A reduces tumor growth [69, 72]. Based on these observations we 
investigated the role of KDMs in oxygen-dependent retinal diseases. 
Hemangioblastomas (also known as the blood vessel tumor or VHL disease) are 
multisystem tumor syndromes, where mutations in the VHL protein (pVHL) lead to 
constitutive activation of the HIF pathway. In patients with mutated pVHL, even though 
HIF-α gets hydroxylated at the proline residues under normoxia, it is not bound by 
mutated pVHL, allowing it to escape proteosomal degradation. Subsequently, HIF-α 
translocates to the nucleus, dimerizes with the HIF-1β subunit, and recruits 
transcriptional co-activators. The active HIF-α/β heterodimer binds to a core DNA 
sequence (G/ACGTG) in the hypoxia-response-element (HRE) present in the promoters 
of target genes, causing overexpression of hypoxia response genes, which includes a 
number of pro-angiogenic factors [e.g. vascular endothelial growth factor (VEGF), 
erythropoietin (EPO), platelet-derived growth factor (PDGF) etc.]. As a result, 
hemangioblastomas of retina, central nervous system (CNS), and kidney are highly 
vascular in nature [115]. 
In addition to these vascular cells, hemangioblastomas are composed of ‘stromal 
cells’. However, the cytological origin of these neoplastic stromal cells remains 
unknown. A number of studies have shown coexistence of pro-angiogenic and stem cell 
markers in tumorlet-like stromal cells in the retinal and optic nerve hemangioblastomas 
[116, 117], leading to the suggestion that hemangioblastomas originate from 
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developmentally arrested stem cells or embryonic progenitors [116-119]. Failure to 
specify the histological origin of stromal cells in hemangioblastomas has precluded the 
development of nonsurgical therapies for these multisystem blood vessel tumor 
syndromes. 
All current therapies for hemangioblastomas and oxygen-dependent retinal 
diseases have significant limitations and side-effects; while anti-VEGF therapies (e.g. 
Macugen, Lucentis, etc.) had minimal detectable beneficial effects [120, 121]. This lack 
of efficacy of anti-VEGF therapies is possibly due to overexpression of other pro-
angiogenic factors (e.g. EPO, PDGF, etc.). Hence, blocking of a master regulator like 
HIF pathway could be a viable alternate strategy for treating pathological conditions 
like hemangioblastomas and oxygen dependent retinal diseases.  
In the first part of the study we evaluated the response to hypoxia in human 
retinal pigment epithelial cells. We also determined the levels of induction of a panel of 
histone demethylases in these RPE cells along with known HIF target genes. Further 
using a generic KDM inhibitor like DMOG resulted in inhibition of JMJD1A target 
gene expression, suggesting the possible use of KDM inhibitors to block amplification 
of HIF pathway. 
Screening for inhibitors of the HIF pathway was performed as a collaborative 
project with Divya Teja Vavilala. We identified honokiol, a biphenolic phytochemical 
extracted from the Magnolia genus (which has been used for thousands of years in the 
traditional Japanese and Chinese medicine) as a potent inhibitor of the HIF pathway. 
We also observed inhibition of the hypoxia-induced expression of histone lysine 
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demethylases in a number of cancer and retinal pigment epithelial cell lines when 
treated with honokiol [122], thus providing an evidence-based scientific explanation of 
honokiol’s therapeutic benefits.  
 In the second part of the study we evaluated the expression of cancer stem cell 
markers in VHL deficient renal cell carcinoma cell lines associated with VHL disease. 
Also, we determined the induction of these CSM markers in RPE cells under hypoxic 
conditions mimicking VHL loss. Further, the efficacy of honokiol’s inhibition of HIF 
mediated induction of CSM markers was compared with digoxin and doxorubicin 
(known HIF inhibitors). 
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Materials and Methods 
Chemicals and reagents 
All chemicals were supplied by the Sigma-Aldrich Chemical Co. (Saint Louis, 
MO) unless otherwise stated, and were of analytical grade or higher. Honokiol was 
purchased from the Stanford Chemicals (Irvine, CA), while digoxin and doxorubicin 
were ordered from Carbosynth LLC (San Diego, CA).  
Cell Culture: 
Human retinal pigment epithelial cell lines (D407 and ARPE19) and renal cell 
carcinoma derived cell lines (RCC4, RCC4-T314, PRC3, and WT8) were used for these 
studies. RCC4 and PRC3 cells lack a functional VHL gene, whereas RCC4-T314 and 
WT8 cells have a wt-VHL incorporated into them. The RCC4, RCC4-T314, PRC3, and 
WT8 cell lines were generously provided by Dr. M. Celeste Simon (University of 
Pennsylvania Cancer Center), while D407 cell line was generously gifted by Dr. 
Richard Hunt (University of South Carolina). DMEM medium, supplemented with 10% 
heat inactivated FBS, 100 µg/ml of streptomycin, and 100 U/ml of penicillin (media 
components were purchased from Corning), was used to grow D407, ARPE19, RCC4, 
and T314. PRC3 and WT8 were maintained in the above mentioned media 
supplemented with 1 mg/ml G418. Cells were cultured in a CO2 incubator that was 
maintained at 37°C, 5% CO2, and 90% relative humidity.   
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Treatment of cells with HIF inhibitors 
Digoxin, Doxorubicin, and Honokiol used for the study were prepared in 
DMSO. Dimethyloxalylglycine (DMOG), a general 2OG-dependent dioxygenase 
inhibitor, was prepared in water. The inhibition studies were carried out by adding 1mM 
DMOG or 1 µM of digoxin or 1 µM of doxorubicin or 20 µM of honokiol in to the 
media in a flask containing ≈70% confluent cells. In the control samples 0.1% of 
DMSO, corresponding to the DMSO concentration in the cells treated with highest 
inhibitor concentration, was added. 
Hypoxia treatment 
Cells were subjected to hypoxic condition using an artificial gas mix of 1% O2, 
5% CO2, and 94% N2 in a Bactron Anaerobic Chamber. Prior to the treatment the 
system was purged to generate the hypoxic atmosphere inside the chamber according to 
the manufacturer’s instructions. Once the cells were ready for treatment (~70% 
confluent), they were aseptically transferred into the chamber through the airlocks to 
maintain hypoxic conditions inside the chamber and incubated for 12 hrs or time 
indicated at 37°C. Cell lysis for RNA extraction was performed after exposure to 
hypoxia for 12 h in the hypoxic chamber to avoid equilibration of the cells to normoxic 
conditions. RCC4, T314, PRC3 and WT8 cell lines were treated in a similar way, albeit 
under normoxic conditions due to absence of wt-pVHL in RCC4 and PRC3, which 
mimic hypoxic conditions with respect to the HIF pathway. 
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RNA Extraction from Cells 
Cells grown under normoxic or hypoxic conditions were lysed in TRI® reagent 
and the lysate was collected into a micro centrifuge tube. Following phase separation 
with chloroform, the aqueous phase containing RNA was separated. To this aqueous 
layer, 100% isopropanol was added to precipitate RNA. The RNA pellet obtained was 
washed twice with 75% ethanol and dissolved in DNase⁄RNase-free water. The 
concentration of RNA was determined using Nanodrop (Thermo Fisher Scientific, 
Wilmington, DE, USA). RNA was reverse transcribed using M-MLV reverse 
transcriptase (Promega). The reverse transcription was initiated by denaturation for 5 
minutes at 70°C followed by reverse transcription for 1 hour at 42°C and final extension 
for 5 minutes at 72°C. 
Quantitative Real time PCR Analysis 
The primers for all the genes analyzed by quantitative real time PCR were 
designed with the primer design tool of Genscript. Two sets of primer pairs from 
different regions were manually selected for each gene. The oligonucleotides were 
synthesized by Integrated DNA Technologies and are listed in Table 6. All the 
quantitative real time PCR reactions were set up in biological triplicates and 
experimental duplicates. Each quantitative real time PCR reaction contained 80 ng of 
cDNA, 2.5 units of Taq polymerase, 0.25mM dNTP, 1X SYBR green and 1.5 µM of 
forward and reverse primers in 20 µl of total reaction volume. The reactions were set in 
a 96 well qPCR plates in a Roche LightCycler 480II qPCR instrument. The reactions 
were carried out with initial denaturation at 95°C for 5 minutes, followed by 45 cycles 
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of denaturation at 95°C for 10 seconds, annealing at 55°C for 10 seconds and extension 
at 72°C for 10 seconds. Ribosomal protein L32 was used as an internal control to 
normalize the sample to obtain ∆Ct value. 2-∆∆Ct method was used to analyze the relative 
gene expression levels.  
Table 6: Sequences of primes used for qPCR analysis for the complete panel of KDMs 
and JMJD1A target genes. 
S.No. Gene - Primer Name Primer Sequence 
1 FBXL10-qPCR-F1 ATGTCCCAGTTTGTGCGTTA 
2 FBXL10-qPCR-R1 TGGTGTGGCTGAACTCTAGG 
3 FBXL10-qPCR-F2 AAGACACGGTGGAAGAGGAG 
4 FBXL10-qPCR-R2 GGTGGATGATTTCATTGCAG 
5 FBXL11-qPCR-F1 TGAAGGAAAGCCAGACTGAA 
6 FBXL11-qPCR-R1 CACCAAAGTCCACATGGAAG 
7 FBXL11-qPCR-F2 CCTGTGTGCAAGGAGAGTGT 
8 FBXL11-qPCR-R2 GACTGAGTGAGGCAGTCTGG 
9 HR-qPCR-F1 AACCTGGGTTGTTTGGCTTA 
10 HR-qPCR-R1 ATCTCTCCATCCCTCTGGTG 
11 HR-qPCR-F2 CTGATGCTGACCCAGTTTGT 
12 HR-qPCR-R2 CGGATATCAAACTTGACCCA 
13 JARID1A-qPCR-F1 AGATGAGGTCACCCGAAGAC 
14 JARID1A-qPCR-R1 AGAGAGTGCCTTTCCGTTGT 
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S.No. Gene - Primer Name Primer Sequence 
15 JARID1A-qPCR-F2 AGGACTCGGACCAAACTGAC 
16 JARID1A-qPCR-R2 GCTGATGACACACGGAAGAC 
17 JARID1C-qPCR-F1 TGGAGTCAACATCGCCTAAG 
18 JARID1C-qPCR-R1 CAATAAACTGGGCATTGCTG 
19 JARID1C-qPCR-F2 TGCTGGAGAAGGGTATCACA 
20 JARID1C-qPCR-R2 CTTGATACACTGGCGCTCAT 
21 JARID1D-qPCR-F1 TTCTGTGATGGCTGTGATGA 
22 JARID1D-qPCR-R1 CTGTTTACACTCCGCCAAGA 
23 JARID1D-qPCR-F2 ACACTCCACAGCTGACCTTG 
24 JARID1D-qPCR-R2 CTTGATAGGCCTCCACCTGT 
25 JARID2-qPCR-F1 TTCTCTGCCTTCGAGGTTCT 
26 JARID2-qPCR-R1 CTGGCATGAAGATGAAGCAT 
27 JARID2-qPCR-F2 CAAGGTGGACACCAACACTC 
28 JARID2-qPCR-R2 ATGGACCCTGTGTTATTGGG 
29 JHDM1A-qPCR-F1 TGAGCGTGAAAGGTTGTTTC 
30 JHDM1A-qPCR-R1 CATGGTACCAAACGGAAGTG 
31 JHDM1A-qPCR-F2 TGCTCAAGGAGCAGAAGATG 
32 JHDM1A-qPCR-R2 GCCTCCTCACACTCACTCCT 
33 JHDM1D-qPCR-F1 GCTCTCGAGTCTTCCCAAGT 
34 JHDM1D-qPCR-R1 TAGGTGAAGGGAGCCTGAGT 
35 JHDM1D-qPCR-F2 TTCGAGCAATAGAGGAGGAAA 
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S.No. Gene - Primer Name Primer Sequence 
36 JHDM1D-qPCR-R2 CATCTTTCTTCGGGAATGGT 
37 JHDM2A-qPCR-F1 AATTGTACAGTGGCCTGCAA 
38 JHDM2A-qPCR-R1 ATCTCCCAGAAAGCGAACAG 
39 JHDM2A-qPCR-F2 CAGCCAGCACATCTCCTCTA 
40 JHDM2A-qPCR-R2 GGATTTGCTTAAAGGTGGGA 
41 JHDM2B-qPCR-F1 CATTCGAGTCTCCATTGCAC 
42 JHDM2B-qPCR-R1 TGAAACAGATGCAACCCATT 
43 JHDM2B-qPCR-F2 TCTCACTGGATGAACGAAGC 
44 JHDM2B-qPCR-R2 CAGCTGCTCCTCAGAGTCAC 
45 JMJD1A-qPCR-F1 TCTGAGGCCTCTCCCAGTAT 
46 JMJD1A-qPCR-R1 ACTTTGCTGTCTTGGGTCCT 
47 JMJD1A-qPCR-F2 CAGCCAGCACATCTCCTCTA 
48 JMJD1A-qPCR-R2 GGATTTGCTTAAAGGTGGGA 
49 JMJD1B-qPCR-F1 CATTCGAGTCTCCATTGCAC 
50 JMJD1B-qPCR-R1 TGAAACAGATGCAACCCATT 
51 JMJD1B-qPCR-F2 CAGACAGTTCGGCATCAAAT 
52 JMJD1B-qPCR-R2 TTGCTAAATCTGCCAACCAG 
53 JMJD1C-qPCR-F1 TGTAAGCGACCTCGAGAGAA 
54 JMJD1C-qPCR-R1 CGCTCTTTGTCATCAGCACT 
55 JMJD1C-qPCR-F2 GCAAGTGAGCTCAGAAATGC 
56 JMJD1C-qPCR-R2 TCAGAAATCCACAACAAGGC 
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S.No. Gene - Primer Name Primer Sequence 
57 JMJD2A-qPCR-F1 ATCACCATTGAGGGTGTGAA 
58 JMJD2A-qPCR-R1 ATGTCTTCAGTGTGCCAAGC 
59 JMJD2A-qPCR-F2 AGGAAGAGGCTGAGGAGACA 
60 JMJD2A-qPCR-R2 ATACAGACAGCGCAGTGAGG 
61 JMJD2D-qPCR-F1 AAATCCAACGACTCCTGCTT 
62 JMJD2D-qPCR-R1 TTGTAAAGATCGTGGTTGCC 
63 JMJD2D-qPCR-F2 CACCGATTTATGGTGCTGAC 
64 JMJD2D-qPCR-R2 TGACGCCTTCTATGACAACC 
65 JMJD3-qPCR-F1 GGGCAACTGTACGAGTCAGA 
66 JMJD3-qPCR-R1 GAAGCTTCCTCCGTATCGAA 
67 JMJD3-qPCR-F2 GCCGAATTCAAGATCCTACC 
68 JMJD3-qPCR-R2 CGTGTTGTTGCTGTTCCTCT 
69 JMJD6-qPCR-F1 CCGGCACAACTACTACGAGA 
70 JMJD6-qPCR-R1 CTTTCATACCGCTCCACAAA 
71 JMJD6-qPCR-F2 GCCTGTTTCCTACCAGCACT 
72 JMJD6-qPCR-R2 TAGCTTCGTCTTGCTGGTTC 
73 PHF8-qPCR-F1 GGTTTCATGGCAGTTGTGTT 
74 PHF8-qPCR-R1 GGGCAGTGGTAGAGGTCAAT 
75 PHF8-qPCR-F2 GCCTTAACATCGAGATGCAG 
76 PHF8-qPCR-R2 TCTGAAGAGGTCTGCTGTGC 
77 PHF2-qPCR-F1 CCATCCTCGTCCCTAAGAAA 
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78 PHF2-qPCR-R1 TCAGCTTCATCTTGCAGTCC 
79 PHF2-qPCR-F2 TCTCACAAATCTGGGAAGCA 
80 PHF2-qPCR-R2 GCTGTGAAGGTTTGAAGTGC 
81 ADM1-qPCR-F1 CACTTCGGGCTTCTCACTG 
82 ADM1-qPCR-R1 AAAGTCTCAGACGTCCCACTG 
83 ADM1-qPCR-F2 GGTGTCTTCTAAGCCACAAGC 
84 ADM1-qPCR-R2 CTCGGGAAGTCCTTCGTC 
85 EDN2-qPCR-F1 CAGTTCTGTGTCCTCGCACT 
86 EDN2-qPCR-R1 GCAGCCTCCAGATGAATGTA 
87 EDN2-qPCR-F2 CTATGGTCTCCGTGCCTACC 
88 EDN2-qPCR-R2 TTGGGCATGAGATGAGGAC 
89 EDN1-qPCR-F1 TCATGATCCCAAGCTGAAAG 
90 EDN1-qPCR-R1 AGGCTATGGCTTCAGACAGG 
91 EDN1-qPCR-F2 GTTCAGTTTGAACGGGAGGT 
92 EDN1-qPCR-R2 TGAGCTCAGCGCCTAAGAC 
93 GDF15-qPCR-F1 GCTACGAGGACCTGCTAACC 
94 GDF15-qPCR-R1 GAGGTCGGTGTTCGAATCTT 
95 GDF15-qPCR-F2 CAAGAACTCAGGACGGTGAA 
96 GDF15-qPCR-R2 ATCTGGAGTCTTCGGAGTGC 
97 HMOX1-qPCR-F1 GGCTTTATGCCATGTGAATG 
98 HMOX1-qPCR-R1 GTAAGGAAGCCAGCCAAGAG 
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S.No. Gene - Primer Name Primer Sequence 
99 HMOX1-qPCR-F2 CATGCAGCGCTATGTGAAG 
100 HMOX1-qPCR-R2 AGACAGGTCACCCAGGTAGC 
101 SERPENB8-qPCR-F1 CCATTTCTCGTCTCATGCTC 
102 SERPENB8-qPCR-R1 AGGGTTAAATCAGAGGGCAA 
103 SERPENB8-qPCR-F2 CTCGCCGTGAAAGAGTGAT 
104 SERPENB8-qPCR-R2 GGGAGCATGAGACGAGAAAT 
105 SERPINE1-qPCR-F1 CACTGGAAAGGCAACATGAC 
106 SERPINE1-qPCR-R1 TCGTGAAGTCAGCCTGAAAC 
107 SERPINE1-qPCR-F2 GGATGAGATCAGCACCACAG 
108 SERPINE1-qPCR-R2 GGAACAGCCTGAAGAAGTGG 
109 VEGF-qPCR-F2 CTTGCCTTGCTGCTCTAC 
110 VEGF-qPCR-R2 TGGCTTGAAGATGTACTCG 
111 Glut1 – qPCR-F1 CGGGCCAAGAGTGTGCTAAA 
112 Glut1 – qPCR-R1 TGACGATACCGGAGCCAATG 
113 CD24 – F1 TGCTCCTACCCACGCAGATT 
114 CD24 – R1 TCAGAGGAGTAGGAGAGAGGAAAC 
115 CD44 – F1 TCAGAGGAGTAGGAGAGAGGAAAC 
116 CD44 – R1 GAAAAGTCAAAGTAACAATAACAGTGG 
117 NOTCH1 – F1 CACTGTGGGCGGGTCC 
118 NOTCH – R1 GTTGTATTGGTTCGGCACCAT 
119 CD34 – F1 TCCAGAGACAACCTTGAAGC 
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S.No. Gene - Primer Name Primer Sequence 
120 CD34 – R1 CTTCTTAAACTCCGCACAGC 
121 CD144 – F1 TTCATGACGTGAACGACAAC 
122 CD144 – R1 TCCACCACGATCTCATACCT 
123 SOX2 – F1 GTATCAGGAGTTGTCAAGGCAGAG 
124 SOX – R1 TCCTAGTCTTAAAGAGGCAGCAAAC 
125 NANOG – F1 TTTGGAAGCTGCTGGGGAAG 
126 NANOG – R1 GATGGAGGGAGGGGAGAGGA 
127 C-MYC – F1 CGGAACTCTTGTGCGTAAGG 
128 C-MYC – R1 CTCAGCCAAGGTTGTGAGGT 
129 KLF4 – F1 TATGACCCACACTGCCAGAA 
130 KLF4 – R1 TGGGAACTTGACCATGATTG 
131 CD133 – F1 TCCACAGAAATTTACCTACATTGG 
132 CD133 – R1 CAGCAGAGAGCAGATGACCA 
133 OCT3/4 – F1 ACATGTGTAAGCTGCGGCC 
134 OCT3/4 – R1 GTTGTGCATAGTCGCTGCTTG 
135 LGR5 – F1 CTTCCAACCTCAGCGTCTTC 
136 LGR5 – R1 TTTCCCGCAAGACGTAACTC 
137 LEF1 – F1 TCCTGAAATCCCCACCTTCT 
138 LEF1 – R1 TGGGATAAACAGGCTGACCT 
139 TCF7 – F1 CAGCTCCCCCATACTGTGAG 
140 TCF7 – R1 TGCTGTCTATATCCGCAGGAA 
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Results and Discussions 
Validation of qPCR primers 
The RCC4 clear-cell renal cell carcinoma cell line lacks VHL, an ubiquitin ligase, 
responsible for targeting the hydroxylated HIF-α for proteosomal degradation. Hence 
this cell line has stable HIF-α protein even under normoxic conditions, and translocates 
to the nucleus to constitutively activate the HIF pathway similar to the hypoxic 
conditions. T314 cells were derived from RCC4 cells by stably transfecting VHL. These 
cells express normal levels of VHL, and thus, do not activate HIF pathway under 
normoxic conditions. Due to this established link between VHL loss and activation of 
HIF pathway, RCC4 and T314 cell lines are ideal cell-based systems for studying the 
HIF-mediated transcription phenomena [123]. 
The cDNA from RCC4 and T314 cells were synthesized and utilized to validate the 
primers used in this study. In cases where the Ct values (number of PCR cycles elapsed 
before threshold) for the two primer pairs for a same gene were apart by more than 0.5 
cycles, additional primer pairs were designed to produce consistent results by two 
independent primer pairs for the same gene (data not shown). As expected these 
experiments demonstrated an upregulation of a number of Jmj domain containing iron 
(II), 2OG-dependent KDMs in RCC4 cells (Figure 26), which represents the 
constitutively active HIF pathway. These experiments also validated our qPCR primers 
and experimental conditions. 
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Figure 26: Expression of KDMs in RCC4 and T314 cells after 36 hours of culture under 
normoxic condition. RCC4 cells lack VHL, hence possess stable HIF-α protein even 
under normoxic condition and constitutively activate HIF pathway similar to the 
hypoxic conditions. By contrast, T314 cells have stably transfected VHL and hence do 
not activate HIF pathway under normoxic conditions.  
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Hypoxia induces expression of KDMs in retinal pigment epithelial cells 
An activation of the HIF pathway leading to induction of pro-angiogenic genes 
such as VEGF is responsible for a number of hypoxia induced retinal diseases such as 
VHL, proliferative diabetic retinopathy, glaucoma, and retinopathy of prematurity 
[113]. Since retinal pigment epithelial cells are one of the major cell constituents and 
secretor of VEGF in the retina [124], a human retinal pigment epithelial cell line (D407) 
was selected for these studies [125, 126]. These cells are spontaneously transformed 
cells derived from the primary culture of human retinal pigment epithelial cells. Recent 
studies have shown that these cells exhibit high levels of VEGF induction at both 
mRNA and protein levels under hypoxic conditions, and hence serve as a good model 
for evaluating the response of VEGF and other hypoxia regulated genes [125]. 
For all further studies a time course experiment (3, 6, 12 and 24 hours) was 
performed with D407 cells to identify the point where hypoxia responsive genes 
demonstrate the highest induction. For these studies the expression of known hypoxia 
responsive genes (GLUT1 and VEGF) and three KDMs (JMJD2B, JMJD2C and 
JMJD1A) that are direct transcriptional targets of HIF were chosen as markers. These 
experiments showed that the expression of the tested genes peaked after ~24 hours of 
hypoxic treatment (Figure 27). 
Based on these results the expression of the entire panel of KDMs was 
compared under hypoxic (1% O2) and normoxic (21% O2) conditions after 24 hours. 
The Ct values were normalized with their respective internal control (ribosomal protein  
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Figure 27: Time course experiment on D407 cells to determine an appropriate time for 
all further analysis. Three known KDM targets and known hypoxic response genes 
VEGF and GLUT1 were used as markers to determine the time point. Cells were 
harvested at 3, 6, 12 and 24 hrs followed by RNA extraction and qPCR reaction. 
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L32) and fold changes were calculated by comparing the hypoxia treated samples to 
their corresponding normoxia samples. VEGF and GLUT1 genes, known hypoxic 
response genes, demonstrated ~6 and ~8 fold induction, respectively (Fig. 21). In 
addition, transcription of 14 out of the 20 Jmj domain containing iron (II), 2OG-
dependent KDMs (JMJD2B, JMJD1A, JMJD1B, JMJD1C, JARID1A, JARID1B, 
JARID1C, FBXL10, JHDM1D, JMJD3, UTX, HR, JARID2 and JMJD6) showed ≥1.5 
fold induction with both primer pairs under hypoxic conditions (Figure 28).  
 
Figure 28: Expression of histone lysine demethylases in D407 cells with 24 hours 
hypoxia treatment. Ribosomal protein L32 was used as an internal control and all 
samples were normalized to their corresponding normoxia samples whose expression 
level was set to be 1. 
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Out of these 14 KDMs that are induced by hypoxia in retinal pigment epithelial cells, 13 
were also induced in a number of cancer cell lines [127], suggesting an important role 
of these genes in hypoxic adaptation and neovascularization in cancer and retinal 
diseases. JMJD1A exhibited ~6 fold induction under hypoxia by the two independent 
primer pairs (Figure 28), similar to the levels observed for VEGF and GLUT1, 
suggesting a role in regulating the transcription of some important pro-angiogenic genes 
under hypoxic conditions. 
Hypoxia induces expression of JMJD1A target genes in retinal pigment epithelial cells 
Our studies have demonstrated that JMJD1A was one of the strongly induced 
KDMs under hypoxic condition. It is also a direct transcriptional target of HIF-α [69-
71]. JMJD1A (also known as KDM3A or JHDM2A) acts as a coactivator for nuclear 
hormone receptors and regulates transcription by demethylating di- and mono-
methylated histone-3 lysine-9 (H3K9-me2 and H3K9-me) into H3K9, respectively, at 
target promoters [128]. Recent studies have indicated that the expression of a subset of 
hypoxia induced genes (53 out of 821) is dependent on the expression of JMJD1A [69]. 
This subset included well known hypoxia induced genes such as ADM, EDN1, EDN2, 
GDF15, HMOX1, SERPE1 and SERPB8. These genes play critical roles in vascular 
dilation (ADM) [129] and angiogenesis (ADM, EDN1, SERPINE1, and HMOX1) [130]. 
Therefore, to further investigate the role of JMJD1A in angiogenesis under 
hypoxic conditions in D407 cells, we evaluated the induction of ADM, EDN1, EDN2, 
GDF15, HMOX1, SERPE1 and SERPB8, the known targets of JMJD1A. After 24 hours 
of hypoxia treatment, significant induction was noted for these downstream targets of 
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JMJD1A compared to normoxic conditions (Figure 29). These results also confirm a 
role of JMJD1A in hypoxia-mediated transcription. 
 
 
Figure 29: Expression of JMJD1A target genes in D407 cells under hypoxia. Ribosomal 
protein L32 was used as an internal control and all samples were normalized to their 
corresponding normoxia samples whose expression level was set to be 1.  
Effect of dimethyloxalylglycine on JMJD1A-mediated pro-angiogenic gene expression 
The downregulation of HIF pathway can inhibit neovascularization observed in 
cancer and retinal diseases. Since the HIF pathway induces the expression of a number 
of Jmj domain containing iron (II), 2OG-dependent KDMs and other pro-angiogenic 
genes whose expression is dependent on KDMs (such as JMJD1A), we explored if a 
general KDM inhibitor such as dimethyloxalylglycine (DMOG, a 2OG analog; Figure 
30) can inhibit HIF pathway-mediated expression of pro-angiogenic genes.  
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Figure 30: Schematic representation of biochemical reaction carried by iron(II), 2OG-
dependent Jmj histone lysine demethylases (KDMs). Dimethyloxalylglycine (DMOG), 
which gets converted into N-oxalylglycine by cellular esterases, act as a competitive 
inhibitor for 2OG due to structural similarity. 
To evaluate such effect of this general inhibitor on the expression of these 
KDMs and genes regulated by JMJD1A, both normoxic and hypoxic cells were treated 
with 1mM DMOG for 24 hours. These experiments also revealed an overall consistent 
level of KDMs’ induction in DMOG-treated hypoxic cells compared to DMOG-treated 
normoxic cells (Figure 31). Some KDMs showed slightly lower induction in DMOG-
treated hypoxic cells compared to untreated hypoxic cells suggesting a role for other 
iron (II), 2OG-dependent dioxygenases, e.g. AlkB family DNA demethylases (a recent 
paper showed that AlkB5 is also a direct HIF target) in hypoxia-mediated KDMs’ 
transcription [131]. 
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Figure 31: Expression of histone lysine demethylases in D407 cells with 24 hours of 
1mM DMOG treatment under hypoxia and normoxia. Ribosomal protein L32 was used 
as an internal control and all samples were normalized to their corresponding normoxia 
samples whose expression level was set to be 1. 
Importantly, treatment of retinal pigment epithelial cells with DMOG exhibited 
statistically significant inhibition of expression of five (ADM, GDF15, HMOX1, 
SERPE1 and SERPB8) out of the seven (ADM, EDN1, EDN2, GDF15, HMOX1, 
SERPE1 and SERPB8) tested pro-angiogenic JMJD1A target genes (Figure 32). These 
five inhibited genes included both of the known direct transcriptional targets of 
JMJD1A (JMJD1A induces expression of ADM and GDF15 by directly demethylating 
H3K9-me2 and H3K9-me into H3K9 at their promoters) [69].  
98 
 
 
 
Figure 32: Expression of JMJD1A target genes in untreated vs 1mM DMOG treated 
D407 cells under 24 hours hypoxic condition. Ribosomal protein L32 was used as an 
internal control and all samples were normalized to their corresponding normoxia 
samples whose expression level was set to be 1. Student t-test was performed for all the 
samples to determine the statistical significance. * represents P <= 0.05 and ** 
represents P<= 0.001 as compared to untreated samples. 
Thus, our results identify a new layer of epigenetic transcription regulation 
under hypoxia (Figure 33), and suggest that use of specific inhibitors of KDMs such as 
JMJD1A can be a new therapeutic approach to treat a number of diseases caused by the 
hypoxia induced neovascularization. 
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Figure 33: Control of HIF-α by the proline and aspartate hydroxylases. Under normoxic 
conditions (left panel), PHDs and FIH hydroxylate HIF-α on proline (P402/564) and 
aspartate (N803) residues, respectively, leading to ubiquitin ligase VHL E3-mediated 
destruction or inhibition of interaction with the transcription co-activator p300/CBP. 
However, under hypoxic conditions (right panel), these oxygen-sensitive hydroxylases 
become less active, allowing stabilization of HIF-α and its dimerization with HIF-α/β 
leading to transcription of hypoxia response genes, which includes a number of KDMs. 
The expressions of some pro-angiogenic genes are dependent on KDM expression. The 
fragment colors of HIF subunits represent different protein domains. 
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HIF-mediated expression of pro-angiogenic genes in renal cell carcinoma and retinal 
pigment epithelial cell lines 
The human RCC4 cell line lacks wt-pVHL and hence has a constitutively active 
HIF pathway. RCC4-T314 cells were derived from the RCC4 cells by stably 
transfecting wt-VHL, and thus, these cells do not activate the HIF pathway under 
normoxia. Under hypoxia, HIF-α isoforms are stabilized in RCC4-T314 cells leading to 
activation of the HIF pathway [123]; By contrast, 786-O cells, another renal cell 
carcinoma cell line that is also VHL‒/‒, expresses only HIF-2α [132, 133]. Unlike 
VHL‒/‒ RCC4 cells [123], HIF-1α is not detectable in VHL‒/‒ 786-O cells [133]. The 
loss of HIF-1α expression in some VHL‒/‒ RCC cells confers an in vivo growth 
advantage [134], possible due to the role of HIF-1α in apoptosis [108]. Reintroduction 
of wt-VHL in 786-O cells leads to downregulation of HIF-2α protein levels, restores 
normal oxygen-dependent regulation of HIF-2α subunit and transcription of pro-
angiogenic genes which, in turn, suppresses tumor formation in mouse xenografts [132, 
133, 135]. Importantly, a HIF-2α variant, which lacks pVHL-binding sites, prevents 
tumor suppression by exogenously introduced wt-VHL in VHL‒/‒ cells [134, 136]. 
Conversely, downregulation of HIF-2α in VHL‒/‒ cells, similar to the effects observed 
with the reintroduction of wt-VHL in these cells [132, 135], serves to inhibit expression 
of pro-angiogenic genes, inhibits the proliferation of vascular endothelial cells, and to 
suppress tumor growth by VHL‒/‒ cells [137]. Further, HIF-α inactivation abolishes the 
cellular response to hypoxia in vitro, indicating that HIF-α is the only pVHL target 
required for this response, and the tumor forming ability of VHL‒/‒ 786-O cells is 
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dependent on the constitutive activation of the HIF pathway. Due to this established link 
between VHL loss and activation of the HIF pathway, RCC4 and PRC3 (i.e. 786-O 
cells with empty vector) cell lines with their VHL+/+ counterparts (RCC4-T314 and 
WT8) are ideal cell-based system for determining the HIF-mediated transcription 
phenomena. 
The cDNA from RCC4, RCC4-T314, PRC3, and WT8 cells were synthesized 
under normoxic conditions and the level of expressions of pro-angiogenic genes were 
compared. These experiments demonstrated a significant upregulation of a number of 
HIF-dependent pro-angiogenic genes in RCC4 and PRC3 cells compared to RCC4-
T314 and WT8 cells (Figure 34A and Figure 34B), respectively, representing the 
constitutively active HIF pathway in these cells. Our studies also demonstrated that Jmj-
domain containing protein 1A (JMJD1A) was one of the strongly induced histone lysine 
demethylases in VHL‒/‒ renal cell carcinomas cell lines (Figure 26). Recent studies in 
renal cell carcinomas have revealed that higher levels of JMJD1A are present around 
the blood vessels, suggesting its role in angiogenesis [138]. JMJD1A regulates the 
expression of adrenomedullin (ADM) and growth differentiation factor 15 (GDF15) by 
directly binding to their promoters and demethylating dimethylated histone-3 lysine-9 
[69]. These genes play critical roles in HIF-dependent signaling and angiogenesis [139, 
140]. Therefore, we further investigated the expression of these two JMJD1A targets 
and observed significant induction in VHL‒/‒ renal cell carcinoma cell lines compared 
to their VHL+/+ counterparts. Further, since a retinal cell line similar to RCC4 and 
PRC3 cells with respect to VHL inactivation is not available, we determined that 
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treating the human retinal pigment epithelial cell lines (D407 and ARPE-19) with 
hypoxia induces the expression of these pro-angiogenic genes. Similar to the renal cell 
carcinoma cells, our results demonstrated that hypoxia indeed induced the expression of 
pro-angiogenic genes, JMJD1A, and its target genes in these retinal pigment epithelial 
cell lines (Figure 34C and Figure 34D). Overexpression of some of these markers was 
also confirmed at protein levels by western blots (data not shown). 
 
Figure 34: Relative fold change in the mRNA levels of indicated pro-angiogenic genes 
in: RCC4 (Panel A), PRC3 (Panel B), D407 under hypoxia (Panel C), and ARPE19 
under hypoxia (Panel D) in the presence or absence of 1 µM digoxin (DG), 1 µM 
doxorubicin (DX), and 20 µM honokiol. Solid, beveled, grey, and checked bars 
represent relative mRNA fold change ± standard error for control, 1 µM DG, 1 µM DX, 
and 20 µM honokiol treatments, respectively. Normoxic levels are represented by the 
horizontal line. 
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HIF-mediated expression of stem cell markers in renal cell carcinoma and retinal 
pigment epithelial cell lines 
A number of studies have shown a coexistence of pro-angiogenic and stem cell 
markers in hemangioblastomas [116, 117]. Therefore, it has been suggested that 
hemangioblastomas originate from developmentally arrested stem cells or embryonic 
progenitors [116-119]. However, recent studies have shown that the HIF pathway also 
plays a role in the expression of stem cell markers in cancer cells [141, 142]. Therefore, 
we evaluated the extent to which these markers are induced under normoxic conditions 
in VHL‒/‒ RCC4 and PRC3 cells compared to RCC4-T314 and WT8 cells, 
respectively, and under hypoxic conditions in noncancerous retinal pigment epithelial 
cells (D407 and ARPE19). 
For these studies, markers from different pathways downstream to the HIF 
pathway were selected. These markers play important roles in stem cell 
maintenance/differentiation [143], and can be classified into: (i) Wnt pathway markers 
[Lymphoid enhancer-binding factor 1 (LEF1), Leucine-rich repeat-containing G 
protein-coupled receptor 5 (LGR5) and Transcription Factor 7 (TCF7)]; (ii) drug 
resistance proteins [Multi-drug resistance 1(MDR1, also known as P-glycoprotein 1 or 
P-gp), Multidrug resistance-associated protein 2 (MRP2) and Breast cancer resistance 
protein (BCRP)]; (iii) Yamanaka factors [Octamer-binding transcription factor 4 
(OCT3/4), Kruppel-like factor 4 (KLF4), c-myc, and Sex determining region Y-box 2 
(SOX2)]; and (iv) cancer stem cell-associated markers [Aldehyde Dehydrogenase 1 
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(ALDH1), Cluster of differentiation 24 (CD24), Cluster of differentiation 34 (CD34), 
Cluster of differentiation 44 (CD44), Cluster of differentiation 133 (CD133), Cluster of 
differentiation 144 (CD144, also known as VE-cadherin), NANOG, and NOTCH1]. 
Upon activation of the HIF pathway, either due to the loss of functional pVHL 
or due to hypoxia, we detected overexpression of 2 out of 3 Wnt pathway markers (i.e. 
LEF1, LGR5), 1 out of 3 drug resistance proteins (i.e. MDR1/P-GP), and 4 out of 8 
other stem cell/cancer stem cell markers (i.e. CD133, CD144, NANOG, and NOTCH1) 
in most of the cell lines (Figure 35 and Figure 36). In general, over expression of target 
genes was more pronounced when the HIF pathway was activated by the exposure of 
cells to hypoxic condition. Taken together, these results show that mutations in the VHL 
gene leads to the activation of the HIF pathway. This activated pathway induces the 
expression of stem cell/cancer stem cell markers, in addition to overexpression of pro-
angiogenic factors. Thus our results suggest a possible mechanism for the origin of 
neoplastic stromal cells in hemangioblastomas. 
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Figure 35: Relative fold change in the mRNA levels of indicated stem cell/cancer stem 
cell markers in: RCC4 (Panel A) and PRC3 (Panel B) in the presence or absence of 1 
µM digoxin (DG), 1 µM doxorubicin (DX), and 20 µM honokiol. In both panels (i) 
represents Wnt pathway genes, (ii) represents drug resistance genes, (iii) represents 
Yamanaka factors, and (iv) represents cancer stem cell-associated markers. Solid, 
beveled, grey, and checked bars represent relative mRNA fold change ± standard error 
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for control, 1 µM DG, 1 µM DX, and 20 µM honokiol treatments respectively. 
Normoxic levels are represented by the horizontal line. 
 
Figure 36: Relative fold change in the mRNA levels of indicated stem cell/cancer stem 
cell markers in: D407 (Panel A) and ARPE-19 (Panel B) in the presence or absence of 1 
µM digoxin (DG), 1 µM doxorubicin (DX), and 20 µM honokiol under hypoxia. In both 
panels (i) represents Wnt pathway genes, (ii) represents drug resistance genes, (iii) 
represents Yamanaka factors, and (iv) represents cancer stem cell-associated markers. 
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Solid, beveled, grey, and checked bars represent relative mRNA fold change ± standard 
error for control, 1 µM DG, 1 µM DX, and 20 µM honokiol treatments respectively. 
Normoxic levels are represented by the horizontal line. 
Inhibitors of the HIF pathway down-regulates the expression of stem cell marker 
In order to conclusively prove that the transcription of pro-angiogenic and stem 
cell markers is due to the HIF pathway, we evaluated the effectiveness of digoxin, 
doxorubicin, and honokiol, three recently identified HIF inhibitors from natural sources, 
to suppress the transcription of selected markers. We found that all the three HIF 
inhibitors strongly (≈50-90% for most genes) inhibited the expression of HIF-dependent 
transcription of selected markers in the retinal pigment epithelial cell lines (D407 and 
ARPE-19) under hypoxia, and VHL‒/‒ renal cell carcinoma cells under normoxic 
conditions (Figure 34, Figure 35, Figure 36). These results confirm that the inhibition of 
the HIF pathway by digoxin, doxorubicin, and honokiol, is conserved across multiple 
cell lines without any noticeable cytotoxicity under both hypoxic and normoxic 
conditions. Importantly, no significant change in the transcription of HIF independent 
housekeeping genes (ribosomal protein L32, actin and GAPDH) was noted (data not 
shown). These results suggest that digoxin, doxorubicin, and honokiol are not general 
transcription inhibitors, but rather are specific inhibitors for the HIF pathway. 
The treatment of RCC4, RCC4-T314, APRE-19 and D407 cells with honokiol 
under normoxia or hypoxia did not alter their proliferation in cell culture (data not 
shown). These results are consistent with a number of cell-based studies showing that 
the inhibition of the HIF pathway in VHL‒/‒ RCC cells, by reintroduction of wt-VHL in 
108 
 
VHL‒/‒ cells, does not inhibit their proliferation in cell culture [134, 136, 137]. 
However, such inhibition of the HIF pathway abolishes the tumor forming ability of 
VHL‒/‒ 786-O cells in mouse models [134, 136, 137]. Therefore, the inhibitors of the 
HIF pathway evaluated in this study, all of which are used by humans for other 
conditions, can be used for the treatment of pVHL-associated hemangioblastomas. 
VHL disease is an autosomal dominant tumor syndrome with a predilection for 
the retina, CNS, and kidney. The incidence of VHL disease is ≈1 in 36,000, and it is 
estimated that there are ≈7,000 patients with VHL disease in the U.S. alone. The VHL 
disease is associated with significant mortality with an average life-expectancy of 
patients is ≈50 years. The mean age at diagnosis of hemangioblastomas in VHL disease 
is ≈25 years. Ocular hemangioblastoma is observed in up to 85% patients with VHL 
disease and is the earliest manifestation of the disease. The VHL-associated ocular 
hemangioblastomas can cause massive exudation, subretinal edema, inflammation, 
retinal detachment, or glaucoma, resulting in loss of vision. Current treatment with laser 
photocoagulation or cryotherapy can cause subretinal and vitreous hemorrhage. Further, 
using such methods, it is difficult to specifically target and treat optic disc lesions. Anti-
VEGF therapies have been largely ineffective [120, 121], possibly due to contribution 
of other pro-angiogenic factors, such as EPO, PDGF, etc. in hemangioblastomas. Thus, 
there remains an unmet medical need to develop more effective treatments for 
hemangioblastomas. Based on our studies, we propose a model where mutations in the 
VHL gene lead to activation of the HIF pathway in patients with hemangioblastomas. 
This results in the expression of stem cell/cancer stem cell markers, in addition to 
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overexpression of pro-angiogenic factors, in neoplastic stromal cells (Figure 37). 
Finally, the current study evaluates the use of HIF inhibitors as an effective therapeutic 
agent for the treatment of hemangioblastomas, for which limited treatment options are 
currently available. 
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Figure 37: A model showing modulation of the HIF pathway by pVHL under normal 
conditions or in hemangioblastomas. Under normal normoxic conditions (left panel), 
PHDs hydroxylate HIF-α on proline (P405/531) residues, leading to ubiquitin ligase 
pVHL E3-mediated destruction of HIF-α. However, in patients with mutations in 
pVHL, although HIF-α gets hydroxylated at the proline residues, it escapes proteosomal 
degradation, allowing its translocation and dimerization with HIF-β in the nucleus 
leading to transcription of hypoxia response genes even under normoxic conditions, 
which includes a number of pro-angiogenic and stem cell markers in neoplastic stromal 
cells in hemangioblastomas (right panel). The fragment colors of HIF subunits represent 
different protein domains. 
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CHAPTER IV 
DEVELOPMENT OF A HPLC BASED METHOD FOR EVALUATING THE 
CATALYSIS BY TET2 DNA DEMETHYLASE 
Introduction 
Cytosine methylation at carbon-5 is an important covalent modification of 
mammalian DNA. Methylation of DNA at cytosine carbon-5 in the CpG dinucleotides 
is carried by DNA methyltransferases [144] . Due to the critical role played by the 
human DNA methyltransferases in normal development and disease states, numerous 
studies were directed toward the identification of 5mC demethylases. Ultimately, using 
sophisticated bioinformatics tools three putative DNA modifying enzymes, TET1-3, 
were identified in the mammalian genomes [28]. Biochemical characterization of the 
newly identified putative DNA modifying enzymes showed that TET1 hydroxylates 
5mCs into 5-hydroxymethylcytosines (5hmCs) both in vitro and in mammalian cells 
[24]. A significant genomic presence of 5hmC (~0.6% of all Cs; accounting for ~40% 
of all 5mCs) was also observed in Purkinje cells from the mouse cerebellum [26]. TET1 
is highly expressed in embryonic stem cells (ESCs), and several studies have used high 
quality TET1 antibodies to characterize TET protein binding and 5hmC deposition 
across the mESC genomes using parallel DNA sequencing technology [145-148]. These 
studies have shown that TET1 binds predominantly to CpG islands and TET1-bound 
promoters show significantly lower levels of 5mC marks, possibly due to TET1-
mediated demethylation. Surprisingly, given the established role of 5mC in gene 
112 
 
repression, all these studies have shown that the knockdown of TET1 causes more 
genes to be de-repressed than de-activated. 
The TET1 gene was initially identified as a fusion partner of the MLL 
(myeloid/lymphoid or mixed lineage leukemia) gene in acute myeloid leukemia (AML) 
[149]. Using cytogenetics and single nucleotide polymorphism arrays, we and others 
have shown that TET2 is one of the most frequently mutated genes in myelodysplastic 
syndromes (MDS) [150-152]. The TET2 mutations are also prevalent in a number of 
myeloid malignancies such as MDS-myeloproliferative neoplasms (MDS-MPN) and 
acute myeloid leukemia derived from MDS and MDS-MPN (sAML) [152]. Patients 
with TET2 mutations show low levels of genomic 5hmC in the marrow compared to 
those with wild-type TET2 [150]. 
Role of TET2 oxygenase in hematopoiesis 
In order to determine the function of TET2 in normal hematopoiesis and myeloid 
transformation, a number of groups have generated TET2-knockout mouse models 
[153-156]. These studies showed that TET2 was highly expressed in hematopoietic 
stem cell (HSC) and other progenitor cells, and that ablation of TET2 dramatically 
diminished the levels of genomic 5hmC in bone marrow cells. Importantly, in contrast 
to TET1-knockout mouse model [157], which shows some reduction in the cellular 
5hmC levels but are viable, fertile and appear to develop normally, TET2-knockout 
mice developed diverse myeloid malignancies. Although TET2-knockout mice are 
viable and grossly normal, as they age, they start dying from different hematopoietic 
malignancies.  
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Results from studies of TET2-knockout mice suggest that wild-type TET2 
promotes hematopoietic differentiation. TET2 loss resulted in an expansion of the HSC 
and other myeloid progenitor cell numbers. TET2-deficient HSC and progenitor cells 
also showed progressively diminished hematopoiesis. TET2–/– and TET2+/– HSCs had a 
higher ability to self-renew, providing a competitive advantage to these cells compared 
to wild-type HSCs for repopulating hematopoietic lineages. Further, consistent with a 
high percentage of patients with heterozygous TET2 alterations, heterozygous cells 
from TET2+/− mice behaved similar to TET2−/− cells and developed diverse myeloid 
malignancies. TET2+/− cells also exhibited a competitive advantage over wild-type 
TET2 cells in transplantation assays, although this occurred over a longer period 
compared to TET2−/− cells. These results suggest that TET2 haploinsufficiency is 
sufficient to change the properties of HSCs leading to induction of myeloid 
malignancies. 
Other genes also play a role in the maintenance of 5hmC levels in cells (Figure 
38). For example, the normal function of isocitrate dehydrogenases (IDH1/2) is to 
convert isocitrate into 2-oxoglutarate (2OG). In some AML and glioblastoma patients 
mutations in IDH-1/2 create neomorphic variants of the enzymes, which produce 2-
hydroxyglutarate (2HG) instead of 2OG [158]. Due to the structural similarity with 
2OG, 2HG binds in the 2OG binding pocket in the active site of dioxygenases, which 
impairs their function. Thus, 2HG acts as a competitive inhibitor for a number of 2OG-
dependent dioxygenases like histone lysine demethylases (KDMs), prolyl hydroxylases,  
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Figure 38: Mutations in the enzymes of TCA cycle can influence the activity of Fe(II), 
2OG-dependent dioxygenases involved in epigenetics causing cancers. Normally 
IDH1/2 converts isocitrate to 2OG, while in subsequent steps succinate is converted to 
fumarate by succinate dehydrogenase (SDH) and fumarate to malate by fumarate 
hydratase (FH). Mutations in the SDH and FH genes lead to accumulation of succinate 
and fumarate, respectively, while mutations in IDH1/2 gene allow neomorphic enzymes 
to convert isocitrate in to 2HG. Accumulated succinate, fumarate or 2HG, due to 
structural similarity with 2OG, act as competitive inhibitors of 2OG-dependent 
dioxygenases leading to changes in the epigenetic landscape. Mutated enzymes and 
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their altered substrates or products are represented in red font. The substrates of Fe(II), 
2OG-dependent dioxygenases involved in epigenetics are shown in bold blue font. 
 
and DNA demethylases like TET2 [159, 160]. Inhibition of dioxygenases such as 
KDMs and TET2 leads to an increase in the histone lysine methylation and a decrease 
in the 5-hydroxymethylcytosine levels in cells. Thus, clinical features of some IDH1/2 
gain-of-function mutations are similar to TET2 mutations in AML patients.  
Other key TCA cycle enzymes (e.g. succinate dehydrogenase, SDH, and 
fumarate hydratase, FH) are also mutated in various cancers [161, 162]. Mutations in 
these enzymes lead to cellular accumulation of succinate and fumarate, respectively. 
Due to structural similarity with 2OG, these TCA cycle intermediates inhibit the 
activity of dioxygenases like prolyl-hydroxylase-domains (PHDs) resulting in pseudo-
hypoxic environment and activation of hypoxia-inducible-factor (HIF) pathway leading 
to aberrant cellular proliferation [163] (Figure 38). It would be interesting to check the 
status of these enzymes in leukemia patients and evaluate their effects on TET 
dioxygenases. 
Three-dimensional topology of TET dioxygenases 
A comparison of primary sequences of a number of Fe(II), 2OG-dependent 
dioxygenases reveals some conserved motifs (e.g. iron and 2OG binding), but with little 
primary sequence similarity among different subfamilies [164]. Yet, the reported crystal 
structures of Fe(II), 2OG-dependent dioxygenases have demonstrated an emergence of 
a common structural platform among different subfamilies. The results from these 
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studies have revealed a β-strand core containing eight anti-parallel β-strands folded into 
a “Jelly-roll” motif. This characteristic motif harbors the dioxygenase active site 
consisting of three residues (two histidine and one aspartate or glutamate residues 
known as the “2-His-1-carboxylate triad”) occupying one side of the Fe(II) coordination 
sphere [52]. The residues which constitute the 2-His-1-carboxylate triad are generally 
present on or near the relatively rigid β-strand core, indicating a divergent evolution 
within the 2OG-dependent dioxygenase subfamilies. 
Bioinformatics analyses followed by secondary structure predictions suggest the 
existence of a similar Jelly-roll motif containing the 2-His-1-carboxylate triad (His-
1672×Asp-1674…His-2028 in TET1; His-1382×Asp-1384…His-1881 in TET2; His-
942×Asp-944…His-1538 in TET3) in the active site of TET dioxygenases (Figure 39). 
This 2-His-1-carboxylate triad forms a common Fe(II) binding platform, which allows 
dioxygenases to carry out a range of oxidation reactions [164]. The Fe(II) metal center, 
locked in the 2-His-1-carboxylate triad, binds three exogenous ligands (i.e. 2OG and 
O2) on the other side. Thus, oxygen binds to the metal center trans to any residue 
constituting the 2-His-1-carboxylate triad. The remaining two Fe(II) coordinates are 
occupied by the carboxyl and keto oxygen atoms of 2OG (Figure 3). The 5-carboxylate 
group of 2OG binds to either an arginine (present on the eighth β-sheet of the Jelly-roll) 
or a lysine (present on the fourth β-sheet of the Jelly-roll) residue from the enzyme. 
Thus, based on the binding of 5-carboxylate group of 2OG two subfamilies of Fe(II), 
2OG-dependent dioxygenases have been identified. In TET dioxygenases, the 5-
carboxylate group of 2OG binds an Arg residue. In some dioxygenases where the 5-
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carboxylate group of 2OG binds an Arg residue, a characteristic Arg×Ser motif is found 
where the Ser residue forms an additional hydrogen bond with the 5-carboxylate group 
of 2OG (Arg-2043×Ser-2045 in TET1, Arg-1896×Ser-1898 in TET2, Arg-1553×Ser-
1555 in TET3). 
 
Figure 39: A graphical representation of the full-length TET2 showing the cysteine rich 
domain and catalytic dioxygenase domain (A). An active site representation of TET2 
showing the eight antiparallel β-sheets constituting the Jelly-roll motif (B). The Jelly-
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roll motif also represents the bound cosubstrate, 2OG, and cofactors, Fe(II) and O2, to 
the active site catalysing the conversion of 5mC into 5hmC. 
Structure-function analysis of TET2 mutations in leukemia  
The clinically described TET2 mutations include frame-shift, nonsense and 
missense mutations. Since the dioxygenase domain is present toward the TET2 C-
terminus with the critical 2OG binding motif located toward the very end, most frame-
shift and nonsense mutations upstream to it will result in an inactive enzyme. In 
addition to the frame-shift and nonsense mutations, most of the identified TET2 
missense mutations are clustered in the dioxygenase domain (Figure 38). Interestingly, 
some of the most frequently mutated residues (Asp-1384Val, His-1881Gln/Arg/Ala) 
and (Arg-1896Met/Ser/Gly, Ser-1898Phe) form the Fe(II) (His-1382×Asp1384…His-
1881) and 2OG (Arg-1896×Ser-1898) binding motif in the TET2 active site, 
respectively. Since it has been shown that inactivation of TET2 alone can cause myeloid 
malignancies in the mouse model, some of the observed clinical heterogeneity in 
patients with TET2 mutations could be due to the type of the enzymatic defects. 
 In the current study, we cloned and expressed a catalytically active hTET2 gene 
fragment using both baculovirus and bacterial systems. We also developed a HPLC 
method for evaluating the catalysis of the purified hTET2 protein. 
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Materials and Methods 
Cloning of human TET2 
Human cDNA clone for TET2 gene coding for 2420 bp fragment starting at 
3590 bp and ending at 6009 bp was used as the template for PCR amplification. Using 
5’ – TET2-XhoI, AflII, SmaI, SalI: 5’ GTCGACACCCGGGACTTAAGCTCGAGATG 
GGGCATCATCATCATCATCATAAGTGGGTGGTTCGCAGA – 3’ as 5’ primer and 
3’ – TET2-KpnI, NotI: 5’ – ATGATGGCGGCCGCGGTACCTCATATATATCTGTT 
GTA – 3’ as the 3’ primer, 2420 bp hTET2 fragment (fragment A) was PCR amplified. 
The amplified DNA fragment was gel purified and cloned into pGEM®-T vector 
(Promega, Madison, WI). Positive clones were verified by sequencing. To include the 
cysteine rich domain of hTET a 982 bp long fragment (fragment B) was custom 
synthesized and cloned into pUC57 vector. The 3’ end of this fragment B overlapped 
into the 5’ side of the 2420 bp cloned fragment A such that the unique SgrAI site 
present at 192 bp of fragment A was included for joining the two fragments. Fragment 
B was joined to fragment A on the 5’ side by digesting the two vectors with SacI and 
SgrAI. The resulting pGEMT clone consisted of the final 3141 bp long hTET2 fragment 
(fragment C). Generation of this final clone was confirmed by sequencing the clone. 
Confirmed fragment C was transferred into pGEX-4T1 vector to generate pGEX-4T1-
hTET2 bacterial expression construct. Also hTET2 fragment C was transferred into 
pFASTBAC-1 vector by digesting with SalI and NotI enzymes.  
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Bacmid generation 
Verified hTET2 clones in pFASTBAC-1 vector were transformed into 
DH10Bac competent cells and platted on selection media containing kanamycin, 
gentamycin, and tetracycline at 50 µg/ml, 7 µg/ml, and 10 µg/ml respectively. IPTG 
(0.1M) and X-gal (20 mg/ml) (40 µl each) were spread on the plates prior to spreading 
the transformation mix for blue white selection. The plates were incubated for 48 hrs at 
37°C and white colonies were picked. White colonies obtained after 48 hrs of 
incubation were re-streaked onto LB-Kanamycin, Gentamycin, Tetracycline plates with 
IPTG and X-Gal added and incubated for 12-16 hrs at 37°C. Colonies which remained 
white were selected for growing liquid culture and bacmid was extracted from them. 
Presence of TET2 fragment in the extracted bacmids was verified by performing PCR 
analysis using M13 forward and reverse primers to generate a 5414 bp fragment or by 
using a combination of M13 primers and TET2 specific primers. 
Insect Cell Culture 
SF9 cells were obtained from Expression Systems (Davis, CA). They were 
maintained in suspension culture using serum free media (Expression systems, Davis, 
CA) at 27°C with 130 rpm in a New Brunswick shaker for efficient aeration. Cells were 
maintained at a density of 1 million cells per ml by diluting the cultures every second 
day. Cells were allowed to grow to a maximum density of 4-5 million cells per ml.   
Virus generation 
SF9 cells were platted at a density of 900,000 cells per well in a 6 well plate for 
transfecting with pFASTBAC-1 vector carrying human TET2 gene fragment. DNA and 
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celfectine were added into 100µl of transfection media in separate tubes and left at room 
temperature for 5 mins. DNA:celfectine complex was generated by mixing these two 
solutions and leaving for 30 mins at room temperature. Final complex was added to the 
cells and incubated for 4-5 hrs in transfection media. Following this media was changed 
to complete media and incubated for 3-5 days. Once the size of the cells increased 
compared to the untransfected cells, virus was harvested by collecting the spent media. 
Media was spun down to precipitate any debris or cells. The clear supernatant 
containing the virus was tittered to determine the viral titer in the initial stock (P0).  
Using this P0 stock secondary infection of cells was performed in suspension 
culture to amplify the viral titer. For this 30 ml of media was seeded with cells at a 
density of 1 million cells per ml and allowed to grow over night. Once the cells started 
to divide 0.5 ml of P0 was added and the cell count was observed over the next 3-4 days. 
If the cell count crossed 4 million per ml, then not enough of initial virus stock was 
added and if the count didn’t reach 3-4 million per ml, too much viral stock was added. 
Based on this the amount of virus to be added could be adjusted to obtain optimal 
infection of cells for P1 generation. After 4-5 days of infection, virus is harvested by 
spinning the culture and collecting the supernatant. Titer of the generated P1 viral stock 
was determined. 
Protein expression in insect cells 
SF9 cells growing in log phase were seeded at a density of 1 million cells per ml 
in 300 ml of media and allowed to grow overnight at 27°C with agitation. Following 
this after verifying that the cell numbers increased to 1.5-2 million cells per ml, they 
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were infected with desired volume of P1 viral stock for obtaining an MOI of 0.3. After 
infecting the cells, they were cultured for 3-4 days and the cell number and cell size was 
monitored every day. Cells were harvested once the cell number started to drop and the 
size increased to ≈	 20 µm due to high degree of infection. Following this, cells were 
lysed in lysis buffer and processed for western blot analysis. 
Protein expression in bacterial system 
The bacterial construct coding for hTET2 (pGEX-4T1-hTET2) was transformed 
into BL21DE3 cells and selected on ampicillin plates. Using selected colonies small-
scale protein expression was done in 10 ml culture. Cells were grown to an OD600 of 0.8 
at 37°C and then maintained at 16°C. Once the temperature came down to 16°C, 0.1 M 
IPTG was added to induce protein expression. Cells were harvested after 16 hrs of 
incubation. Following this, cells were lysed in SDS gel loading buffer and loaded onto a 
SDS-PAGE to check for induction of hTET2 protein. Western blot analysis was also 
performed to confirm the presence of hTET2 in the induced sample. 
Protein purification 
Recombinant hTET2 protein was purified from 12 liter of culture. Bacterial cells 
were pelleted and either stored at –80°C or lysed immediately for protein purification. 
This step onwards all the steps of protein purification were performed on ice. The cells 
were resuspended in 50 ml of lysis buffer (20 mM Phosphate buffer, pH 7) and 
sonicated at an intensity of 5 for 6 mins with 6 pulses every 30 seconds (Sonic 
Dismembrator 550, Fisher Scientific). The lysate was spun down at 15,000 rpm for 20 
min (Beckman J2-HS centrifuge) and the supernatant was collected and filtered through 
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0.45µ filter. Ion exchange chromatography was employed to purify GST tagged hTET2 
protein, as the theoretical pI of the protein is 8.3. CM-Sepharose (Pharmacia now GE 
Healthcare, Piscataway, New Jersey) was used for the purification. The resin (50 ml) 
was packed into a XK16 FPLC column (Pharmacia now GE Healthcare, Piscataway, 
New Jersey) and equilibrated in 10 bed volumes of wash buffer (20 mM Phosphate 
buffer, pH 7) using an Akta FPLC system (Pharmacia/GE Healthcare). A constant flow 
rate of 1 ml/min was used for all steps. Clarified cell lysate was loaded onto the column 
and washed with the wash buffer (~ 10 bed volumes) till the flow through was clear. 
Elution of the bound protein was carried out using a gradient from the wash buffer to 
the elution buffer (20 mM Phosphate buffer, 1 M Sodium Chloride, pH 7). 0 to 100% of 
elution buffer was reached in 5 bed volumes, followed by holding at 100% elution 
buffer for 4 bed volumes and then dropping down to 0% elution buffer in 3 bed volumes 
and holding there for another 3 bed volumes. Samples of cell lysate before and after 
column loading, along with all the elution fractions (10 ml each) were collected and 
analyzed by SDS-PAGE. 15% glycerol was added to the protein, and aliquotes were 
stored at –80°C. 
HPLC method for Oligonucleotide separation 
A liquid chromatography method for separation and quantification of intact 
oligonucleotide sequences was developed using a Phenomenex Gemini 5µ C18 column. 
Triethylamine acetate buffer system in combination with acetonitrile was employed for 
separation. Solvent A was composed of 100 mM triethylamine acetate pH 7.0 with 5% 
acetonitrile and solvent B was composed of 100 mM triethylamine acetate pH 7.0 with 
124 
 
20% acetonitrile. Column was equilibrated by running 70% of A and 30% of B for 5 
mins and then going upto 80% B in the next 45 mins. Over the next 5 mins solvent B 
concentration was brought down to 50% and then held there for another 10 mins. 
Detector was set up at 260 nm to monitor oligonucleotides. 
Preparation of standard samples for HPLC method validation 
All the nucleoside standards (2’-Deoxyadenine monohydrate, Thymidine, 2’-
Deoxyguanosine monohydrate, 2’-Deoxycytidine and 5’ Hydroxymethyl-2’-
deoxycytidine) were purchased from Berry and Associates (Dexter, MI). All 
nucleosides except 2’-Deoxyguanosine monohydrate were prepared in HPLC grade 
water. 2’-Deoxyguanosine monohydrate was prepared in acidified water (pH 4.5) and 
used immediately. Nucleoside standards ranging from 900 µM to 10 mM in 
concentration were prepared for validating the HPLC method and evaluating the limits 
of detection and quantification. 
HPLC method for analyzing nucleosides 
A liquid chromatography method was developed to separate all the individual 
nucleosides from a mixture. Using a Phenomenex Gemini 5µ C18 column a gradient 
method was employed to separate the nucleosides using a flow rate of 0.5 ml per minute 
with solvent A being 10mM ammonium acetate, pH 4.0 and solvent B being 100% 
acetonitrile with 0.1% acetic acid added. The time profile for the method is as follows: 
100% solvent A was run for the first 3 minutes followed by a gradient to reach 5% 
solvent B in 20 minutes. This was followed by holding 5% solvent B for 3 minutes and 
then dropping to 0% solvent B (100% solvent A) in the next 2 minutes. The column was 
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allowed to equilibrate in solvent A for the next 10 minutes. The UV detector was set at 
280 nm for the detection.  
DNAse I digestion of oligonucleotide 
An oligonucleotide of 32 mer was used as the template for doing the digestion 
with DNAse I. DNAse I works on both single and double stranded DNA to yield 5’-
phosphomononucleotides and oligonucleotides. The digestion of the single stranded 
oligonucleotides was setup using varying concentration of the enzyme ranging from 2 
units to 10 units at 37°C for 12 hours. 10 µg of the substrate was used for all the 
digestions. Following the digestion half of the sample was processed by phenol 
chloroform and precipitated using isopropanol and the remaining half was used directly 
for calf intestinal alkaline phosphatase (CIAP) treatment. 
Calf intestinal alkaline phosphatase (CIAP) treatment 
Conditions for calf intestinal alkaline phosphatase treatment were initially 
standardized by using commercially available dCTP. For the phosphatase treatment 2-
10 units of CIAP was used with 10 µg of dCTP (substrate) for 12 hours. Following this 
the samples were purified by phenol chloroform extraction, precipitated with 
isopropanol and finally re-suspended in 10 µl of water. DNAse I digested samples were 
further processed to remove the phosphate group by treating with CIAP. Crude and 
phenol chloroform extracted samples were subjected to CIAP treatment for 12 hours 
and were processed as mentioned earlier. 
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Mass Spectrometric analysis 
Adenosine, Thymidine, Guanosine and Cytidine standards were dissolved in 
water and infused into the mass spectrometer (MS) in the positive mode as these lacked 
the phosphate group. To analyze the digested and CIAP treated oligonucleotide samples 
using either MS or MALDI-TOF we performed HPLC purification. Fractions were 
collected and the solvent was evaporated using speed vac. Following this samples were 
re-suspended in nuclease free water and analyzed. 
Demethylation reaction 
All demethylation reactions were performed in duplicate in 100 µl reaction 
volume with final concentrations of 500 µM FeSO4, 1 mM 2-oxoglutarate, 2 mM 
ascorbate, 50 mM HEPES, pH 7.5, and 40 µg of purified enzyme. 2 µg of annealed 
double stranded oligonucleotide with single methylated CpG island was used as the 
substrate in the assay. The reactions were carried out at 37 °C for 12 hrs.  Following this 
the reaction mix was processed as mentioned earlier for DNAseI digestion for 12 hrs 
and CIAP treatment for 12 hrs. The reaction mix was purified and used for HPLC 
analysis as mentioned earlier. 
qPCR analysis 
Using RNA extracted from cells exposed to hypoxia in earlier studies as 
described in materials and methods section of chapter 3, we performed qPCR analysis. 
Primers used for this study are listed below in Table 7 
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Table 7: Sequences of primes used for qPCR analysis of TET1-3 DNA demethylases. 
S.No.	   Gene - Primer Name	   Primer Sequence	  
1	   TET1-­‐F1	   TAGCCCAACTCTCTCAGGCT	  
2	   TET1-­‐R1	   AGGAGGTACTGACCATTGGC	  
3	   TET1-­‐F2	   AGTCCTTAACCTGCAATGGG	  
4	   TET1-­‐R2	   GGAGAGTCGCCTGCTAAGAG	  
5	   TET1-­‐F3	   TTCCAGTCCAAGGAGAGGTC	  
6	   TET1-­‐R3	   GGAACAGGAAGGAAGACAGG	  
7	   TET1-­‐F4	   CAAAGTTCATGCAACACGGT	  
8	   TET1-­‐R4	   TGACTTTGTGGATGCTTGGT	  
9	   TET2-­‐F1	   GTGAGATCACTCACCCATCG	  
10	   TET2-­‐R1	   CAGCATCATCAGCATCACAG	  
11	   TET2-­‐F2	   AAATGAATCAAGGGCAGTCC	  
12	   TET2-­‐R2	   AGAAGTGCACCTGGTGTGAG	  
13	   TET2-­‐F3	   TCAACAGCTCTCTTCATGCC	  
14	   TET2-­‐R3	   TCCTTGGACACAAGCAGTTC	  
15	   TET2-­‐F4	   GGAAGTTTAAGCTGCTTGGG	  
16	   TET2-­‐R4	   ATGCATCAGGTGCAAGTTTC	  
17	   TET3-­‐F1	   AAGTTTGGGAACAGCACCTC	  
18	   TET3-­‐R1	   TCTTGGAACCCAGGACTACC	  
19	   TET3-­‐F2	   CATGGTATGAAACCACCCA	  
20	   TET3-­‐R2	   ACTCGAGGTAGTCAGGGCA	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S.No.	   Gene - Primer Name	   Primer Sequence	  
21	   TET3-­‐F3	   GTGGTGGAGAGCTACTCGGT	  
22	   TET3-­‐R3	   ACGCTGTTCATGCTGTAAGG	  
23	   TET3-­‐F4	   AAGGCTGAGAACCCACTCAC	  
24	   TET3-­‐R4	   CAGGTGTGTCCAGCAGACTC	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Results 
Cloning of hTET2 and mTET2 fragments 
The C-terminal human TET2 fragment was PCR amplified using the MGC 
clone as the template (Figure 40). PCR product was cloned into pGEMT cloning vector 
as described in the materials section. The clone was confirmed by restriction digestion  
 
Figure 40: PCR amplification of 2420 bp hTET2 fragment using MGC clone as the 
template. Lane M – 1Kb ladder and lanes 1-4 PCR product 
and positive clones were sent for sequencing (fragment A, Figure 41). Fragment of the 
hTET2 gene containing the cysteine rich region and overlapping with the 5’ side of the 
fragment A was custom synthesized (fragment B) (Figure 42). Fragment A and 
fragment B were combined together using SgrAI and SacI restriction sites present in 
both fragments to generate a 3141 bp fragment C (Figure 42). Obtained clones were 
double digested using an internal enzyme to release a 2 Kb fragment confirming the 
M   1    2    3    4
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generation of the pGEMT-hTET2 (fragment C) clones (Figure 43). Multiple clones 
were sent for sequencing for verifying the presence of the entire 3141 bp fragment C. 
Verified clones were used as the source of the hTET2 fragment for transferring into 
pFASTBAC1and pGEX-4T1 vectors as described in methods section (Figure 43 and 
Figure 44).  
 
Figure 41: pGEMT-hTET2 double digest for confirming positive clones (Lanes 3-6) 
 
M      1      2       3      4      5       6      7
M    1     2      3           4      5     6
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Figure 42: pGEMT-hTET2 (2420 bp) digest for adding synthetic fragment into it. Lane 
M – 1Kb ladder, lanes 1-3 double digest of pUC57-Synthetic TET2 with SacI and 
SgrAI and lanes 4-6 double digest of pGEMT-hTET2 (2420bp) with SacI and SgrAI 
 
Figure 43: pGEMT-hTET2 (3141 bp) internal digest for confirmation. Lane M – 1Kb 
ladder 
 
M      1     2      3     4 
M    1     2     3    4
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M 1  2  3  4  5  6
Figure 44: pFASTBAC-1-hTET2 (3141 bp). Lane M – 1Kb ladder and lanes 1-4 
pFASTBAC1-hTET2 double digested with SalI and NotI 
 
 
 
 
 
 
 
 
Figure 45: pGEX4T1-hTET2 (3141 bp). Lane M – 1Kb ladder and lanes 1 and 6 double 
digest  
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Protein expression in insect cells 
Bacmids encoding for hTET2 protein were generated by transforming the 
pFASTBAC-1 constructs into DH10Bac cells as mentioned earlier. Bacmids extracted 
from the colonies were screened for the presence of TET2 gene using PCR analysis. 
Multiple bacmids were positive for the presence of TET2 gene. Two of these bacmids 
were used for transfecting SF9 cells for virus generation as described in the methods 
section.  
 
 
 
 
 
 
 
 
 
Figure 46: PCR analysis of bacmids extracted from DH10Bac cells transformed with 
various constructs of TET2. PCR for the top set was done using M13 forward primer 
and gene specific reverse primer and the expected amplicon size is ≈ 5.5 Kb. PCR for 
the bottom set was done using gene specific forward and reverse primers and the 
expected amplicon size is ≈ 3 Kb.	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After the transfection the initial viral stock (P0) that was generated had a titer of 
3.97 X 107 pfu/ml. Using P0 virus more cells were infected at an MOI of 0.1 to generate 
amplified viral stock (P1). The titer for P1 was found to be 1.23 X 109 pfu/ml. Using P1 
viral stock, 300 ml of log phase cells were infected and harvested as described earlier 
for protein expression analysis. Western blot was performed to detect the presence of 
hTET2 protein in the lysate of the infected SF9 cells (Figure 47). 
 
 
 
 
 
 
 
 
Figure 47: Western blot analysis of cell lysate from SF9 cells infected with TET2 
expressing viral particles. Rabbit anti-TET2 polyclonal antibody was used for the 
detection. 
Protein expression and purification of hTET2 using bacterial system 
C-terminal fragment of hTET2 coding for cysteine rich domain and the 
dioxygenase domain cloned into pGEX-4T1 vector was used to express the protein in 
BL21DE3 cells as mentioned earlier. Small scale expression done in 100 ml culture 
validated the expression conditions. Western blot analysis showed increased expression 
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0 hrs 12	  hrs 16	  hrs
of hTET2 at 16 hrs (Figure 48). Large scale expression of wild type, RM, SF and RMSF 
mutant proteins was done in 12 liters of culture and the protein was purified (>90% 
purity) using CM-Sepharose resin. The total size of the GST-tagged hTET2 protein was 
found to be 145.6 KDa (Figure 49) 
. 
	  
 
	  
 
Figure 48: Western blot analysis of cell lysate from BL21DE3-pGEX-4T1-hTET2. 
Rabbit anti-TET2 polyclonal antibody was used for the detection. 
 
HPLC method for Oligonucleotide separation 
To evaluate the enzymatic activity of TET2 protein we wanted to develop a 
HPLC based analytical method for monitoring the catalysis. We looked at developing 
an ion-pairing system to effectively separate oligonucleotide substrate and product. For 
this purpose we utilized TEAA buffer system along with acetonitrile. We were able to 
separate the complementary forward and reverse strands of a double stranded 
oligonucleotide (Figure 50). Using this method we were unable to separate the 
methylated and unmethylated single stranded oligonucleotides. Hence, we had to look 
at developing an alternative method for evaluating the catalysis by TET2. 
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GST-­‐hTET2
145.6	  KDa
 
 
 
 
 
 
 
 
 
Figure 49: SDS-PAGE analysis of fractions collected during ion exchange purification. 
Fraction with the desired protein is highlighted in the box. 
HPLC method for analyzing nucleosides 
As we were not able to separate methylated and unmethylated oligonucleotides 
using the TEAA buffer system, we looked at developing an HPLC method for 
evaluating individual nucleosides. An HPLC method was developed using pure 
nucleosides as starting material for separating and quantitating. Initially we used 
phosphate buffed as the solvent system and obtained good resolution for the separation. 
Fractions collected after chromatography with the phosphate buffer system gave poor 
results in mass spectrometry analysis (data not shown). Hence phosphate buffer was 
replaced with ammonium acetate, which could be removed by drying the fractions in 
speed vacuum instrument. Using the conditions mentioned in the methods section we 
obtained good separation of all the nucleosides. 
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Figure 50: HPLC chromatogram for a mixture of forward and reverse strands separated 
using TEAA buffer system on a C18 reverse phase column. 
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Methylated	  and	  Unmethylated	  
Oligonucleotides
 
 
 
	  
	  
	  
	  
	  
	  
	  
	  
 
Figure 51: HPLC chromatogram for a mixture of methylated and unmethylated 
oligonucleotides analyzed using TEAA buffer system on a C18 reverse phase column. 
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Figure 52: LC profile of a mixure of nucleoside standards resolved using the developed 
HPLC method. 
The limit of detection (LOD) and limit of quantification (LOQ) of these individual 
nucleosides were determined and listed in Table 8. Multiple concentrations of the 
individual nucleosides were prepared and each nucleoside at each concentration was run 
for 5 times to determine LOD and LOQ. The standard plot for these runs is shown in 
Figure 53.  
2’-­‐ deoxycytidine
5-­‐hydroxymethyl-­‐2’
-­‐ deoxycytidine
Thymidine
2’-­‐ deoxyguanosine
2’-­‐ deoxyadenosine
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Table 8: Limit of detection and limit of quantification of nucleosides calculated using 
the developed HPLC method 
Nucleotide LOD (ng/ml) LOQ (ng/ml) 
Adenosine 30 90 
Thymidine 560 1680 
Guanosine 50 150 
Cytidine 120 360 
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Figure 53: Standard plot for calculating LOD and LOQ of the nucleosides using the 
developed HPLC method.  
Adenosine Guanosine
Thymidine Cytidine
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Calf intestinal alkaline phosphatase (CIAP) treatment 
Commercially available dCTP was run on the HPLC method developed for 
nucleosides. dCTP eluted at 7.3 minutes as seen in Figure 54. The amount of CIAP 
needed for compete conversion of 10 µg of dCTP to deoxycytidine was standardized to 
be 10 units when treated for 12 hrs at 37°C. Following the CIAP treatment the samples 
were purified as mentioned in the methods section and run on HPLC. More than 90% of 
dCTP was converted to deoxycytidine and eluted at 14 minutes as seen in Figure 55. 
 
Figure 54: HPLC chromatogram for dCTP 
	  
	  
143 
 
	  
Figure 55: HPLC chromatogram for dCTP treated with 10 units of CIAP. 
DNAse I digestion of oligonucleotide 
Single stranded oligonucleotide was used as the substrate for the digestion. 
Using varying concentrations of DNAseI, we standardized the DNAseI concentration 
needed for efficient digestion of the substrate to be 10 units. The reactions were carried 
out at 37°C for 12 hrs. Following this samples were subjected to CIAP treatment as 
described earlier and processed for HPLC analysis. We were able to visualize all four 
nucleosides clearly resolved on the HPLC profile (Figure 56). 
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Figure 56: HPLC profile of DNASe I digested and CIAP treated oligonucleotide 
showing individual nucleosides. 
Mass spectrometry analysis 
Mass spectrometry and MALDI-TOF analysis was performed to look for the 
presence of nucleosides in the processed samples. Initially individual nucleoside 
standards were infused into the mass-spectrometer for determining the MS conditions. 
HPLC method was modified such that all the nucleosides elute in a short duration 
facilitating collection of all the nucleosides together as one fraction (Figure 57). 
Infusion of the processes fraction showed the presence of all four nucleosides (Figure 
58). Similar results were obtained when the sample was used for MALDI-TOF analysis 
(Figure 59). 
 
Thymidine
2’-­‐ deoxycytidine
2’-­‐ deoxyguanosine
2’-­‐ deoxyadenosine
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Figure 57: HPLC profile of DNASe I and CIAP treated oligonucleotide using modified 
method 
Demethylation reaction 
TET2 DNA demethylases work on double stranded oligonucleotides. Using the 
assay conditions described earlier we evaluated the catalysis by TET2. Following the 
incubation with and without the enzyme, oligonucleotide was processed and HPLC 
analysis was performed. The negative control had the signature profile for all the 
standard nucleosides (Figure 60). In the chromatogram for the reaction a new peak at 20 
min was observed which correlates well with the peak for 5-hydroxymethylcytosine, 
one of the reaction products (Figure 61). Identity of the new peak was confirmed by 
performing mass spectrometry analysis of the collected fraction.	  
146 
 
	  
	  
	  
	  
	  
	  
 
 
 
 
Figure 58: Mass spectrometer infusion of the fraction collected from the modified 
HPLC method showing all four nucleosides. 
	  
	  
	  
	  
	  
	  
	  
	  
	  
2’-­‐ deoxycytidine
2’-­‐ deoxyadenosine
2’-­‐ deoxyguanosine
Thymidine
DNase I	  and	  CIAP	  treated	  oligonucleotide
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Figure 59: MALDI-TOF analysis of the fraction collected from the modified HPLC 
method showing all four nucleosides. M represents peaks associated with the matrix, A 
for adenosine, T for thymidine, G for guanidine, and C for cytidine. 
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Cytidine
Adenosine
Guanosine
Thymidine
	  
	  
 
	  
Figure 60: HPLC analysis of demethylation reaction incubated without TET2 (negative 
control). 
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Cytidine
Adenosine
Guanosine
Thymidine
5-hydroxymethylcytidine
	  
	  
 
Figure 61: HPLC analysis of demethylation reaction incubated with TET2. 
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Hypoxia mediated expression of TET family of DNA demethylases 
TET family of DNA demethylases belong to Fe(II), 2-OG dependent 
dioxygenase super family of enzymes. Members of this super family are intimately 
involved in the regulation and amplification of the HIF pathway. Hence we evaluated 
the possibility of HIF mediated regulation of TET enzymes in cells originating from 
different tissues. There was a tissue specific induction of TET enzymes when exposed 
to 1 % O2 for 12 hrs suggesting a possibility of HIF mediated regulation (Figure 62). 
	  
Figure 62: qPCR analysis of expression levels of TET1-3 DNA demethylases mRNA 
under 1% O2 in A) 293 cells, B) D407 cells, C) HT29 cells, and D) MCF-7 cells. 
Horizontal line represents normoxic expression levels of the corresponding mRNA. 
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Conclusion and future perspectives 
5-methylcytosine plays critical role in gene expression and its dynamic 
regulation by TET dioxygenases have opened a new era in epigenetic regulation of 
transcription. More interestingly, discovery of TET dioxygenases have helped identify 
three additional cytosine modifications (5hmC, 5fC, and 5caC), with the possibility of 
each playing a distinct role in epigenetics. Recent studies have established that HIF 
pathway plays critical roles in the homeostasis of HSCs, which reside within hypoxic 
regions of the bone marrow [165]. The HIF pathway itself is regulated by and regulates 
a number of dioxygenases [112, 166]. For example, isozymes of PHD and factor-
inhibiting-HIF (FIH) dioxygenases negatively regulate the HIF pathway in response to 
increasing oxygen concentration. The apparent KM values of PHDs and FIH for oxygen 
are in the range of 65-240 µM depending on the substrate and enzyme used [167-169]. 
Since the KM values of PHDs and FIH for oxygen are higher than the observed 
physiological oxygen concentration of 30-60 µM, these enzymes are the cellular oxygen 
sensors. Further, we and others have shown that hypoxia-mediated activation of the HIF 
pathway leading to the induction of iron(II), 2OG-dependent KDMs is a conserved 
process [122, 166]. Recent studies have shown that the apparent KM of Jmjd2 family 
KDMs for oxygen ranges between 50-200 µM, suggesting that KDMs may also 
function as cellular oxygen sensors [170]. Since dioxygenases, including TETs, have an 
absolute requirement of oxygen, it will be interesting to see if oxygen availability plays 
a role in the regulation of TET2 activity during hematopoiesis. Our unpublished data 
indicates differential expression of TET isoforms under hypoxic conditions in cell 
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lineages from diverse origin. However, it is not known if TET isoforms are targets of 
the HIF pathway. Finally, a recent study has shown that in some hypoxic cells 2HG 
accumulates even in the presence of wild-type IDH1/2 [171]. Although the amount of 
2HG in these cells is much lower than that observed in IDH-1/2 mutated AML and 
glioblastoma patients, whether these levels of 2HG are enough to inhibit TET2 activity, 
and thereby, keep HSCs undifferentiated under hypoxic conditions remains to be seen. 
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